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Summary 
        Neurodegenerative disorders such as Parkinson’s disease (PD), Alzheimer’s 
disease (AD) and stroke have seriously influenced the lives of aged people. One of the 
most important aspects of neuroscience research is to exploit the pathogenesis of these 
diseases and ultimately develop therapeutics to prevent the initiation of 
neurodegeneration or protect target neurons from the diseases. Therefore, an 
understanding of the mechanisms contributing to neurodegeneration would provide 
indications to the development of management.  
    The degeneration of dopaminergic neurons after 1-methyl-4-phenyl-1,2,3,6- 
tetrahydropyridine (MPTP)-treatment in the substantia nigra pars compacta (SNc) of 
mice has been well documented. However, the mechanisms underlying the 
degeneration remain poorly understood. An inflammatory process in the central 
nervous system (CNS) is believed to play an important role in the pathway leading to 
neuronal cell death in a number of neurodegenerative diseases. Therefore, this study 
has first aimed to investigate the role of innate immune system on the dopaminergic 
neuron degeneration in the MPTP-induced PD model. Taken into consideration the 
important role of inflammation in PD, immune modulation would be an effective 
therapeutic strategy to protect dopaminergic neurons from further attacks. 
Mesenchymal stem cells (MSCs) have recently been reported to have an immune 
modulatory effect both in vitro and in vivo and after transplantation, MSCs can 
migrate to the impaired regions mediated by chemokine-chemokine receptor 
interactions. The second aim of this study is to investigate whether the transplanted 
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MSCs could protect the dopaminergic neurons from MPTP toxicity through 
modulating the process of inflammation. 
        After MPTP treatment, the author has observed the disruption of 
blood-brain barrier (BBB) integrity, infiltration of mannose binding lectin (MBL), 
activation of microglia, and infiltration of natural killer (NK) cells, as well as loss of 
tyrosine hydroxylase (TH) positive dopaminergic neurons in the SNc. The 
dopaminergic neuron loss was confirmed from the observation of a degenerative 
morphology and significant reduction in the number of TH positive neurons in the 
SNc after MPTP-treatment. Immunohistochemistry showed that the microglial cells 
became ameboid morphologically and the number of major histocompatibility 
complex Class II (MHC II) positive cells increased in the SNc after MPTP-treatment. 
Both Western blot analysis and immuno-electron microscopy (EM) results showed the 
significant decreases in expression of tight junction molecules such as claudin 1, 
claudin 5 and occludin in the BBB. Functional analysis of leakage of fluorescent 
labeled albumins from blood vessels further confirmed the compromise of the BBB 
integrity. The upregulation of expression of MBL in the liver was induced by MPTP 
treatment as shown by Western blot analysis. While immunohistochemistry showed 
that MBL was co-localized with MHC II positive microglial cells in the SNc of 
MPTP-treated mice, real-time RT-PCR did not find mRNA expression of MBL in the 
brain parenchyma, suggesting the infiltration of MBL from the circulation into the 
brain. MBL may play an important role in the activation of microglia. 
Immunohistochemistry also revealed migration of NK cells into brain parenchyma as 
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a consequence of increase in permeability of the BBB. The NK cell activation is 
mediated via natural-killer group 2 member D (NKG2D) receptor. Rae-1γ, one of the 
NKG2D ligands, was found to co-localize with TH neurons in the SNc of 
MPTP-treated mice, indicating that direct interaction between NK cells and impaired 
TH neurons in the pathogenesis of MPTP-induced PD. 
        The immune potential of MSCs and the therapeutic of MSCs transplantation 
on the model of MPTP-treated mice have been investigated in the present study. The 
author demonstrated, using enzyme-linked immunosorbent assay (ELISA), 
immunohistochemistry and electrophoretic mobility shift assay (EMSA), the 
expressions of cytokines IL-6 and TGF-β1 in MSCs under the stimulation of 
lipopolysaccharide (LPS) in vitro through nuclear factor kappa B (NFB) signaling 
pathway. Systematic administration of MSCs rescued the dopaminergic neurons from 
MPTP toxicity, which was shown by the prevention of decrease in the number of TH 
positive neurons after transplantation. The results have suggested possible 
mechanisms, including the following aspects: 1) The expressions of tight junction 
molecules claudin 1, claudin 5 and occludin as well as the BBB function were 
restored; 2) The MBL expression in liver tissue decreased and infiltration of MBL into 
parenchyma decreased after MSC transplantation; 3) Microglial and NK cell 
activation were suppressed as shown by the decreased immune staining of MHC II 
and NKG2D, respectively; 4) Immunofluorescence identified that the transplanted 
MSCs could express IL-6 and TGFβ1 in vivo, suggesting the possibility of MSC 
directly influencing the above mentioned processes.  
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    However, no neuronal marker was found to be co-localized with the 
transplanted MSCs in the SNc of MPTP-treated mice at different time points (3, 7, 14 
and 28 days post-MPTP-treatment), casting doubt on using MSCs for cell replacement 
therapy. Furthermore, the author demonstrated that the MSCs isolated from 
neurofilament light chain (NFL) deficient mice carry on the same genetic deficiency 
and when transdifferentiation induced with retinoic acid (RA), these NFL-/- MSCs 
also could express neuronal marker plus formation of perikaryal protein aggregations, 
which were observed in the motor neurons of NFL-/- mice. This finding further urges 
scientists to consider seriously the quality of stem cells in cell replacement strategy in 
the treatment of various diseases or injuries in the future. 
These studies above suggest that the innate immune system activation, such 
as microglia, MBL and NK cells, as well as the BBB integrity compromise may take 
part in the pathogenesis of MPTP-induced mouse model of PD. MSC transplantation 
could rescue the MPTP-induced dopaminergic neuron degeneration. However, the 
therapeutic effect of MSCs transplantation may not have resulted from the neuronal 
differentiation but resulted from the modulation of MSCs on the innate immune 
system and the recovery of BBB. Further investigations are necessary to understand 
the underlying signaling pathway(s) of MPTP-induced innate immune system 
activation as well as the mechanisms of MSC immune modulation. 
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Parkinson's disease (PD), first described by James Parkinson in 1817, is the 
second most common neurodegenerative disorder after Alzheimer´s disease. It affects 
approximately 1% of the population by the age of 65 years, increasing to 4% to 5% of 
the population by the age of 85 years (Dawson and Dawson, 2003). The prevalence 
rate in those aged 50 years old and above in Singapore is 3.0‰ and increases with age 
(Tan et al., 2004).The neuropathological hallmarks are characterized by progressive 
loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) with the 
presence of Lewy bodies (LB) and dystrophic Lewy neurites in surviving neurons 
(Robinson, 2008), which lead to irreversible dopamine loss in the striatum. After 
about 50% of the dopaminergic neurons and 75-80% of striatal dopamine are lost, 
patients start to exhibit the classical symptoms of PD including motor impairments 
involving resting tremor, bradykinesia, postural instability and rigidity along with 
non-motoric symptoms like autonomic, cognitive and psychiatric problems.  
Great strides have been made in development of agents to treat this 
neurodegenerative disease; however, current therapeutic strategies for PD primarily 
focus on reducing the severity of its symptoms using dopaminergic medications. 
Although this treatment can provide substantial benefits for patients, these agents are 
burdened by adverse effects and long-term complications (Grosset et al., 2005). 
Clinicians and scientists cannot address the underlying problems associated with PD, 
i.e. the progressive loss of dopaminergic neurons because the etiology and 
pathogenesis of PD are still largely unclear.  
In this chapter, the current understanding of etiology and pathogenesis of 
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PD, the application of animal models for studying PD, and possible therapeutic 
application of stem cells in the treatment of PD will be reviewed. Based on this review, 
the scope of the present study will be presented. 
 
1. Etiology of PD 
Up-to-date, the etiology of PD basically includes both genetic and 
environmental factors. Gene mutations are reported to be the leading causes for the 
familial Parkinson’s disease. More and more environmental toxins have been found to 
be related to PD. Although the combination of genetic and environmental factors may 
result in the onset of the PD, the etiology for most classical Parkinsonism is still 
unknown. In this review, the present author will focus on the potential role of the 
genetic mutations and the environment in the development of Parkinson’s disease, 
which will lead to a better understanding of how genetic predisposition and 
genetic/environmental interactions may ultimately contribute to the pathogenesis of 
the disease. 
 
1.1. Genetic mutations in PD  
Numerous attempts have been made to identify the etiology of PD since its 
first description in 1817. Until the end of last century the influence of heredity was 
controversial, however, identification of mutations in several genes responsible for 
PD confirms the role of genetics in this disease development. Here, the author 
review the current understanding of the gene products linked to familial PD (Table 1, 
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PARK1, 2, 6, 7 and 8) with an emphasis on their normal function and pathogenic 
dysfunction contributing to the pathogenesis of PD. 
1.1.1. PARK1 (α-Synuclein, SNCA, PARK4) 
Alpha-synuclein gene was the first gene to be unequivocally associated 
with familial Parkinson’s disease (Polymeropoulos et al., 1997) and codes for a 
presynaptic protein which is thought to be involved in neuronal plasticity. The 
protein is abundantly expressed in neurons, where it is believed to play a role in 
synaptic vesicle recycling, storage and compartmentalization of neurotransmitters 
and associates with vesicular and membranous structures (Cabin et al., 2002). 
Alpha-synuclein has an increased propensity to aggregate due to its hydrophobic 
non-amyloid-b component domain. The presence of fibrillar a-synuclein as a major 
structural component of LB in PD suggests a role of aggregated α-synuclein in the 
pathogenesis of PD (Periquet et al., 2007). Although it is still controversial whether 
the α-synuclin aggregates that lead to LB-like inclusions are toxic or protective in 
PD (Colapinto et al., 2006), much work has indicated α-synuclein mutations are 
responsible for synaptic pathology and neurodegeneration (Cookson and van der 
Brug, 2006; Periquet et al., 2007; Jiang et al., 2007). 
In addition, α-synuclein was also reported to cause neuroinflammatory 
processes which may also play a role in the pathogenesis of PD (Klegeris et al., 2006; 
Reynolds et al., 2008). 
1.1.2. PARK2 (Parkin, an E3-ubiquitin ligase) 
        Parkin is expressed in neurons and functions as an E3-type, E2 
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enzyme-dependent ubiquitin ligase that is involved in the proteasomal degradation of 
target proteins (Hattori et al., 2000; Yao et al., 2004). Several putative substrates of 
Parkin have been identified, and accumulation of these proteins is proposed to 
contribute to the selective death of neurons in humans (Moore, 2006). The 
neuroprotective potential of Parkin has recently been confirmed in different animal 
models (Chung et al., 2004; Palacino et al., 2004; Vercammen et al., 2006). Mutations 
in the Parkin gene are a common cause (10-20%) of early-onset Parkinsonism 
worldwide (Kitada et al., 1998).  
1.1.3. PARK6: PTEN-induced kinase 1(PINK1) 
        PINK1 is a mitochondrially localized protein kinase that is ubiquitously 
expressed in the human brain (Valente et al., 2004), and it is considered to be 
neuroprotective. PINK1 presumably exerts its neuroprotective effect by 
phosphorylating specific mitochondrial proteins and, in turn, modulating their 
functions. A number of tested mutations lead to a decrease in the mitochondrial 
membrane potential under stress conditions (Giasson, 2004). 
1.1.4. PARK7: DJ-1 
DJ-1 is ubiquitously expressed and has been initially described in 
association with oncogenesis and male rat infertility. The protein, however, has also 
been shown to confer chaperone-like activity, and to function as an intracellular 
sensor of oxidative stress (Giasson, 2004). The neuroprotective role of DJ-1 against 
oxidative stress was also supported by the detection of increased DJ-1 levels in 
cerebrospinal fluid (CSF) of sporadic Parkinson’s disease patients and that it was most 
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pronounced in the early stages of the disease (Waragai et al., 2006). A direct link to 
impaired dopamine synthesis in humans with DJ-1 mutations has recently been 
suggested by the finding that DJ-1 regulates the human tyrosine hydroxylase promoter 
(Zhong et al., 2006)., Wild-type DJ-1 was also reported to dramatically improve the 
Parkinsonism phenotype in a 6-OHDA rat model ( Inden et al., 2006).  
1.1.5. PARK8: leucine-rich repeat kinase 2 (LRRK2) 
The multidomain LRRK2 is a cytoplasmic protein with various conserved domains 
and is detectable in Lewy bodies (Ross et al., 2006; Gilks et al., 2005 ). It functions as 
a protein kinase, mutations of which augment its phosphorylation activity and cause 
neuronal degeneration. Mutations in the LRRK2 gene are considered one of the most 
commonly known genetic causes of Parkinsonism (Gilks et al., 2005; Haubenberger 
et al., 2007).  
 
1.2. Environmental factors related to PD  
Besides the genetic factors, evidence from epidemiological investigations 
suggests that more and more environmental toxins such as herbicide paraquat (PQ), 
the fungicide maneb (MB) (Saint-Pierre, 2006) and drug abuse have been found to be 
related to PD in people who have been exposed to them. These environmental factors 
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2. Animal models 
Animal models are an important aid to study pathogenic mechanisms and 
therapeutic strategies in human diseases. Since the pathogenesis and therapy of PD 
are still not well understood to date, it is of great importance to develop animal 
models for the treatment of this disease. A variety of experimental PD models has 
been established using pharmacological agents or environmental toxins in different 
species. The following sections of this review will discuss the advantages and 
disadvantages of the most commonly used animal models of PD and their potential 
roles in revealing the pathogenesis of PD together with the possible therapeutics.  
2.1. The 6-OHDA model 
6-hydroxydopamine (6-OHDA) was the first chemical agent that was 
discovered to have specific neurotoxic effects on catecholaminergic pathways 
(Butcher，1975). Since systemically administered 6-OHDA is unable to cross the 
blood-brain barrier, it has to be injected stereotactically into the substantia nigra, the 
nigrostriatal tract or the striatum to induce the dopaminergic neuron degeneration, and 
subsequently the striatal dopamine depletion (Simola et al., 2007). Usually 6-OHDA 
is injected in one hemisphere while the other side serves as an internal control. 
Unilateral injections lead to asymmetric circling motor behavior after administration 
of dopaminergic drugs, which cause physiologic imbalance between the lessioned and 
the unlessioned striatum (Da Cunha et al., 2008). And this circling behavior can be 
quantified and correlates with degree of lesion. However, the 6-OHDA model does 
not mimic all the clinical and pathological characteristics of PD, and the acute nature 
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of this model differs from the progressive degeneration of the dopamineric neurons in 
PD. 
2.2. The MPTP model 
Drug abusers of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
injection developed clinical symptoms similar to sporadic PD in human (Langston et 
al., 1983). Consequently, it has been demonstrated to exert similar effects in a number 
of other primates (Kolata, 1983; Burns et al., 1983), as well as in cats, and in several 
rodents (Chiueh etal., 1984; Heikkila et al., 1984). In rodents, it has been shown that 
only specific strains of mice are sensitive to the administration of MPTP (McLaughlin 
et al., 2006; Boyd et al., 2007). Thus, researchers established an animal model of PD 
with MPTP-treated mice based on this discovery. After systemic administration 
(subcutaneous, intraperitoneal, intravenous or intramuscular), MPTP crosses the 
blood-brain barrier and is metabolized in astrocytes by monoamine oxidase-B 
(MAO-B) to its active metabolite, 1-methyl-4-phenyl-2,3-dihydropyridinium ion 
(MPP+), which can bind to dopamine transporter and selectively taken up by 
dopaminergic neurons (Watanabe. et al. 2005). MPP+ toxicity is believed to inhibit 
mitochondrial complex I of the mitochondrial electron transport chain (ETC), which 
are found in PD patients, and lead to oxidative stress. Although complex I inhibition 
by MPP+ reduces energy production within dopaminergic neurons, it is likely that this 
is not the immediate cause of the dopaminergic neuronal death. 
MPTP administration into animals is one of the most common models used 
to study PD. It has been used with various doses and regimens (acute versus chronic) 
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by different laboratories. Acute MPTP administration results in specific degeneration 
of about 50%-93% of the dopaminergic neurons in the SNc and more than 99% loss 
of dopamine in the striatum. The schematic drawing of mechanism(s) of 
MPTP-induced cell death (Fig. 1) indicates a great amount of cross-talk between the 
neurons and the non-neuronal milieu. For those drug abusers, autopsies done years 
later after they developed Parkinsonism demonstrated activated microglia in the SN 
similar to that observed in PD cases (Langston et al, 1999). Animal model also 
illustrates that an acute insult to the SN can result in a sustained inflammatory 
response (Barcia et al., 2005; Sawada et al., 2007). It is therefore conceivable that in 
PD, as in humans, primates and rodents exposed to MPTP, an acute insult initiates an 
inflammatory reaction that becomes self sustaining after the initiating agent has 
disappeared. The MPTP model of PD has been invaluable in the studying of the 
mechanisms of PD pathogenesis, for example, the mechanisms of microglial 
activation and their potential damage to the adjacent dopaminergic neurons. 
Less is known about the role of astrocytes than microglia, but they are 
known to secrete both inflammatory and anti-inflammatory molecules and may play a 
role in modulating microglial activity. Oligodendrocytes do not seem to play a role in 
promoting inflammation although, like neurons, they may be damaged by 
inflammatory processes. 
This model has also been useful for testing potential therapeutic regimens, 
such as drug treatments, cell transplantation and gene therapy (Selley, 2005; Hong et 
al., 2007; Shan et al., 2006). Currently, there is no better or more predictive model for 














Figure1. Hypothetical mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) neurotoxicity. MPTP crosses the blood brain-barrier and is converted to its 
metabolite 1-Methyl-4-phenylpyridinium (MPP+) by glial MAO-B. MPP+ is 
selectively taken in dopaminergic neurons through dopamine transporters and 
accumulated in the mitochondria, where it inhibits Complex I of the mitochondrial 
electron transport chain. The mitochondrial inhibition leads to decreases of oxygen 
consumption and ATP production. Oxidative stress generated by MPP + and ATP 
decrease finally lead to cell death. (Watanabe et al., 2005) 
 
2.3. The rotenone model 
The role of environmental toxins in the development of PD has been 
delineated by recent studies. Rotenone, a pesticide and potent inhibitor of complex I, 
has been used as a novel chemical to induce PD models (Adam, 2000; Betarbet et al., 
2000; Giasson and Lee, 2000). Chronic exposure to low dose of rotenone results in 
uniform inhibition of complex I throughout the rat brain but selective degeneration of 
the nigrostriatal dopaminergic neurons, selective striatal oxidative damage, and 
formation of ubiquitin/α-synuclein-positive inclusions in nigral cells, which are 
similar to the Lewy bodies of PD patients (Betarbet et al., 2000).  
The rotenone model appears to be an accurate model in that systemic 
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complex I inhibition results in specific, progressive and chronic degeneration of 
dopaminergic neurons in the nigrostriatal pathway similar to that onserved in human 
PD. However, the labor-intensive nature and variability of this model limited its wide 
use. 
2.4. The Paraquat and Maneb 
Another two environmental toxins, the herbicide N,N'-Dimethyl-4,4'-bipyridinium 
dichloride, or paraquat (PQ) and manganese ethylenebisdithiocarbamate, or maneb, 
have emerged as putative risk factors for PD on the basis of their structural 
similarity to MPP+. Combined use of PQ and maneb produced greater effects on 
the dopaminergic system then either of the chemicals alone (Patel et al., 2007; 
Saint-Pierre et al., 2006; Fei and Ethell, 2008). The PQ and maneb models further 
support the theory that environmental toxins might have a role in the pathogenesis 
of PD. 
So far, there is still no perfect model for the study of PD. Here, the author 
employed MPTP-treated mouse PD model to investigate the pathogenesis and 
management of PD. This is due to (1) the relatively low complexity and cost of the 
procedure, (2) the fact that the MPTP-induced lesion is highly reproducible, and (3) 
the varying degrees of dopaminergic neuron degeneration depending on the dosage 
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3. Review on the pathogenesis of PD 
Although the etiologies of PD are multifactorial, they all lead to the 
nigrostriatal dopaminergic neuron death and dopamine depletion in the striatum. 
Emerging evidences suggest that oxidative stress, mitochondrial dysfunction, 
excitotoxicity, aberrant proteolitic degradation and inflammation may be relevant to 
the pathogenesis of PD (Dawson and Dawson 2003). The following review will focus 
on the pathogenesis of PD from both regional and systemic aspects. 
3.1. Neuronal alteration in the SNc of PD 
3.1.1. Loss of dopaminergic neurons and Lewy body formation  
The pathological hallmark of PD consists of severe loss of dopaminergic 
neurons in SNc with a consequent significant depletion of striatal dopamine (Braak, 
2003) and Lewy bodies (LBs) in survived dopaminergic neurons. LBs are 
intracytoplasmic inclusion bodies composed mainly of neurofilament-like structures 
that also stain positively for ubiquitin and α-synuclein.Ubiquitin is a protein involved 
in the degradation of cytoplasmic proteins. The function of α-synuclein is still not 
clear. In the healthy brain, α-synuclein is present in the presynaptic terminals in the 
SN and locus coeruleus (Iwai, 1995). It has also been localized to the cytoplasm. The 
exact manner of interaction between ubiquitin, α-synuclein, and microfilament-like 
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3.1.2. Mitochondrial dysfunction and oxidative stress  
Mitochondrial involvement in the pathogenesis of PD is supported by 
post-mortem biochemical studies. A disease specific and drug independent defect of 
the mitochondrial respiratory complex I was found in samples of SN from patients 
who suffered from idiopathic PD (Schapira et al., 1990; Hattori et al. 1991; Schapira 
2006).  
The function of the mitochondrial respiratory complex I can be inhibited in 
dopaminergic neurons by systemic administration of MPTP (Beal 2003; Bonsi et al., 
2006).This meperidine analogue is metabolised to 1-methyl-phenylpyridinium (MPP+) 
by the monoamine oxidase B (MAO-B) in glial cells. MPP+ is subsequently 
selectively taken up by dopaminergic terminals and concentrated in neuronal 
mitochondria, where MPP+ binds to complex I and inhibits the respiratory chain, 
leading to an inhibition of ATP synthesis and generation of free radicals (Langston et 
al. 1999). It has also been shown that chronic infusions of the pesticide rotenone, 
another complex I inhibitor, produce an animal model of PD in rats and cause 
oxidative damage to DJ-1 protein, accumulation of α-synuclein, and proteasomal 
impairment (Betarbet et al., 2000；Sherer et al., 2003). The defect appeared to be 
restricted both to complex I and the SN.  
Although the role of mitochondrial dysfunction and mitochondrial DNA 
(mtDNA) mutations in the pathogenesis of PD remains controversial, PD has been 
associated with several mtDNA mutations (Bender et al., 2006; Luoma et al., 2007; 
Schapira, 2007).  
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A large proportion of individual pigmented neurons containing high levels 
of mtDNA deletions has been recently documented in both aged and PD human SN 
(Bender et al. 2006; Kraytsberg et al. 2006; Reeve et al., 2008) and these results 
suggest that mtDNA deletions may be directly responsible for impaired cellular 
respiration and play an important role in the selective neuronal loss observed in aging 
brain and in PD. 
Moreover, many of the genes associated with PD also implicate 
mitochondria in the disease pathogenesis. At least nine named nuclear genes have 
been identified as causing PD or affecting PD risk. Of the nuclear genes, a-synuclein, 
parkin, DJ-1, PINK1 and LRRK2 directly or indirectly involve the mitochondria 
(Beal 2005; Lin and Beal 2006). 
Although the dopamine system pathology has been emphasized, it is 
becoming increasingly clear that PD is a multi-system neurodegenerative disease 
affecting not only diverse neural pathways but also central and peripheral 
inflammatory cell responses (Zhang et al., 2005; Smeyne et al., 2005). 
3.2. Inflammation as a causative factor in the pathogenesis of PD 
Long considered to be an immune-privileged site because of the presence of 
the blood-brain barrier (BBB) and the lack of a lymphatic system, it is now well 
established that the brain is fully capable of mounting an inflammatory response. 
3.2.1. Immune reaction in the CNS of PD 
A key player in the pathogenesis of PD is the microglial cell, the innate 
immune cell dwelling in the brain. Pio del Rio-Hortega initially described microglia 
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as a separate cell type with differing morphology from other glial cells such as 
astrocytes and oligodendrocytes. Microglial cells are resident immunocompetent and 
phagocytic cells in the central nervous system (CNS), and are thought to mediate the 
innate defence system and thus serve a critical role in normal CNS function (Kim and 
de Vellis, 2005). Additionally, although astrocytes provide homoeostatic control of the 
extracellular environment of the neurons and respond to various stimuli such as 
disease, chemicals or physical damage, microglia also act as scavenger cells in the 
event of infection, inflammation, trauma, ischaemia and neurodegeneration in the 
CNS (Beyer et al., 2000). 
It has been generally believed that microglial cells are formed during 
embryonic development when blood monocytes enter the brain and differentiate into 
resident microglial cells exhibiting the cell surface antigens found on macrophages 
(Kim and de Vellis, 2005). Microglia also play active roles in the programmed 
elimination of neural cells in late embryonic brain development and early post-natal 
brain maturation (Upender and Naegele, 1999; Marín-Teva et al., 2004). 
Resting microglia appear to be highly sensitive to many forms of 
disturbance within the microenvironment of the brain and can be quickly activated 
when pathological events occur, such as infection and inflammation, with a series of 
responses (Wojtera et al., 2005). In their resting state, microglial cells display a 
ramified morphology and a low expression of membrane receptors, which are 
necessary for mediating normal macrophage functions, such as leucocyte common 
antigen (LCA), CD14 and mac-1 (CD11b/CD18) (Kreutzberg, 1996). It has been 
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shown that early microglial activation enhanced the expression of immunoglobulin (Ig) 
G reactivity, CD1 and cell adhesion molecules, such as lymphocyte 
function-associated antigen 1 (LFA-1) (CD11a/CD18), intercellular adhesion 
molecule (ICAM)-1 (CD54) and vascular cell adhesion molecule (VCAM)-1(CD106) 
(Orr et al., 2002). When the activating stimulus continues to present, microglia could 
adhere to neurons (Kreutzberg, 1996) directed by chemokines such as monocyte 
chemoattractant protein-1 (MCP-1) and interferon (IFN)-inducible protein-10 that are 
expressed by the neurons themselves (Aloisi et al., 2000; Aloisi, 2001). 
Furthermore, once activated, the inner cytoskeleton of the microglia 
changes, the cell body becomes enlarged, displaying a macrophage-like appearance 
and an increase in numbers occurs (Raivich et al., 1999). Aloisi (2000) reported that 
ultimately, with the continued presence of the inducing stimulus, the microglia 
maintain this functional transformation with the upregulation of major 
histocompatibility complex class two molecules (MHC II) and inflammatory 
glycoproteins, such as CD40, CD80 and CD86, which provide a powerful stimulus for 
immune cell activation (Aloisi et al., 2000). Moreover, microglia constitutively 
express β2-integrins CD11a, CD11b and CD11c.  Overactivation of complement, as 
is thought to occur in neuroinflammation, may provide ligands for microglial integrins 
(Griffin et al., 2007; Kim and de Vellis, 2005). 
It has been suggested that the number of microglia can decrease and lose 
their activation markers, subsequently returning to the resting state if the activating 
stimulus disappears. However, if the pathologic stimulus is maintained, substantial 
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activation occurs and finally the activated microglia cluster around the damaged 
dopaminergic neurons and become phagocytic (Koning et al., 2007; McGeer an 
McGeer, 2008; Templeton et al., 2008). This combination of released factors and 
surface adhesion to dopaminergic neurons leads to a progressive and irreversible 
neuronal cell death, which is exacerbated by the release of chemoattractants by the 
dying neurons to induce even greater infiltration of the region by activated microglia 
(Aloisi, 2001; Kim and De Vellis, 2005; Sriram et al., 2006). The interaction 




Figure 2. Neuron–microglia interactions in PD. Neurons whose viability has been 
compromised by an intracellular insult such as dopamine-derived metabolites may 
release factors that activate resting microglia. In experimental conditions, microglia 
activated directly by pro-inflammatory agents such as LPS or indirectly by dying 
neurons in human disease may induce or exacerbate neuronal toxicity. This could 
result in a self-amplifying cycle of inflammatory-mediated neurodegeneration. 
(Horald and Lotharius, 2005) 
 
3.2.2. Involvement of systemic immunity 
A systemic inflammatory response results in the production of cytokines, 
such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α 
(TNF-α), which circulate in the blood and communicate with neurons within the brain. 
        Dopaminergic neuron death (PD) 
INTRODUCTION                                                   18 
Recent studies suggest that the BBB is compromised in PD patients (Kortekaas etal., 
2005) and peripheral inflammatory factors may also be involved in the pathogenesis 
of PD (Qin et al., 2007). The cytokines freely diffuse from the blood into the brain 
parenchyma where they may then interact with microglia.  
In addition to the presence of these inflammatory cytokines, other 
inflammatory mediators or ongoing inflammatory processes have also been 
documented, including the deposition of complement components. The numerous 
complement proteins circulate in blood as soluble monomers under physiological 
conditions and activation of them leads to a cascade of events culminating in the 
destruction of the microbial cell surface. There are three pathways to activate 
complement proteins, namely classical, alternative and mannose binding lectin (MBL) 
pathways, which converge at the level of the C3 protein (Bonifati and Kishore, 2007). 
MBL is a liver-derived plasma protein that belongs to the family of collectins 
(Holmskov et al., 2003), and there are two isoforms, MBLA and MBLC, in mouse.  
MBL has two important functions. First, it acts directly as an opsonin promoting 
phagocytosis of foreign material to which it has bound. Secondly, MBL activates the 
complement system via MBL associated serine proteases (MASPs) (Vorup-Jensen et 
al., 2000; Hajela et al., 2002) and amplifies the process of inflammation. Several 
studies show that the complement proteins, such as C1q and MBL, are involved in the 
pathology of neurodegenerative diseases and in initiating microglial activation via 
C1q receptor (C1qR) (Yamada et al., 1992; Yamada et al., 1993; Webster et al., 2001; 
Whitton, 2007). 
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Neuroinflammation appears to be an ubiquitous finding in PD patients and 
experimental models of PD. Phagocyte activation, increased synthesis and release of 
proinflammatory cytokines, complement activation, activation of microglia, and 
release of reactive oxygen species (ROS) have been described (Whitton, 2007).The 
humoral immune reactivity in both idiopathic and genetic cases of PD (Orr et al., 
2005), the appearance of CD8+ T lymphocytes in degenerating nigral neurons 
(McGeer et al., 1988) and the classical complement cascade occurs in nigral Lewy 
bodies (Yamada et al., 1992) in patients with PD all suggest that the pathological 
process of PD may involve the dysfunction of the BBB and peripheral immune 
mediated mechanisms.  
3.3. Impairment of the blood-brain barrier 
Electron microscopy (EM) studies with ferritin and horseradish peroxidase 
have revealed that the BBB is composed of complex microvascular endothelial cells 
that are interconnected by tight junctions (TJ), which prevent the entry of plasma 
components, red blood cells, and leukocytes into the brain parenchyma (Reese and 
Karnovsky, 1967; Brightman and Reese, 1969). Some proteins located at the 
endothelial tight junction and their roles in mediating the BBB breakdown in PD will 
be discussed below. 
The molecular biology of the TJ is quite complex (Wolburg, 2006). The TJ 
proteins and their adaptor molecules, which link the TJ to the cytoskeleton, are often 
affected by diseases of the brain. Figure 3 shows the molecular organization of the 
BBB TJ, which forms a continuous cellular membrane that restricts transport of 
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Figure3. A Simplified Molecular Atlas of the BBB. (A) Tight junctions. (B) 
Carrier-mediated transporters. (C) Active efflux transporters. (Zlokovic, 2008) 
 
Occludin was the first integral membrane protein discovered within the TJ 
of endothelial cells, including the BBB (Furuse et al., 1993). Investigation indicates 
that regulation of occludin expression may be a crucial determinant of the tight 
junction permeability properties of endothelial cells in different tissues (Hirase et al., 
1997). A deletion construct lacking the N terminus and extracellular domains of 
occludin has been known to exert a dramatic effect on the integrity of TJ and cell 
monolayers fail to develop an efficient permeability barrier (Bamforth et al., 1999). 
Deletion of occludin in mice results in a complex phenotype and postnatal growth 
retardation (Saitou et al., 2000).  
Likely, normal expressions and localizations of other junctional proteins 
such as claudin-3, zonula occludens-1 (ZO-1), ZO-2, vascular endothelial cadherin 
(VE-cadherin), and α-catenin may compensate well for the occludin loss (Saitou et al., 
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2000). However, hyperplasia of the gastric epithelium, calcifications in the brain, and 
testicular atrophy found in occludin-deficient mice (Saitou et al., 2000) raise a 
possibility that occludin has some other important physiological roles besides a TJ 
protein. Recent studies have indicated that occludin regulates epithelial cell 
differentiation (Schulzke et al., 2005) and it controls claudin-2-dependent TJ function, 
as well as cell apoptosis through inhibition of mitogen-activated protein kinases 
(MAPK) and Akt signaling pathways (Murata et al., 2005). Whether occludin has a 
role in the BBB differentiation during normal development, brain vascular repair, or 
both, remains to be explored. 
The claudins are a multigene family of more than 20 members that form TJ 
strands through homophilic claudin-claudin interactions mediated by the extracellular 
loop 2 of claudins (Piontek et al., 2008). Claudin-1, -3, -5, and -12 are reported to be 
localized at the BBB (Wolburg et al., 2001, 2003 Nitta et al., 2003;). Each claudin 
regulates the diffusion of a group of molecules of a certain size. For example, mice 
with claudin-5 deletion die as neonates due to a size-selective loosening of the BBB 
for molecules <800 Da (Nitta et al., 2003). 
Claudin-5 was reported to be another tight-junctional protein capable of 
contributing to the "sealing" of the tight junction (Amasheh et al., 2005). Both 
claudin-5 and occludin were found in the surrounding astrocytes, but not in the brain 
endothelium, after the BBB disruption (Yang et al., 2007). It is possible that increased 
levels of occludin found in astrocytes and neurons in vascular dementia, AD, and 
frontotemporal dementia (Romanitan et al., 2007) might reflect the autophagy of the 
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TJ proteins by the surrounding cells after the BBB breakdown. 
Early studies have demonstrated that melanin-containing neurons of the 
SNc have a very close spatial relationship with the blood supply. While in PD 
individuals, normal contact between nigral neurons and capillaries is lost at an early 
disease stage, and capillaries do not maintain their normal shape (Issidorides, 1971). 
Capillary basement membrane thickening and collagen accumulation have also been 
shown in PD (Farkas et al., 2000). These provide us a few more possible approaches 
for the treatment of PD. 
 
4. Review on the management of PD 
Since the discovery of Levo-dopa, a prodrug to increase dopamine levels, 
the development of the PD management has made great progress. However, current 
therapeutic strategies focus primarily on reducing the severity of its symptoms using 
dopamine replacement. Although providing substantial benefits, these agents are 
burdened by adverse effects and long-term complications (Grosset, 2005; Thanvi et 
al., 2007), and cannot address the key issue associated with PD, i.e. the progressive 
loss of dopaminergic neurons. 
4.1. Anti-inflammation 
One approach to this issue has been to investigate whether 
anti-inflammatory drugs might influence progression of the disease or its onset. 
Although retrospective studies suggest that non-steroidal anti-inflammatory drugs 
(NSAIDs) may be neuroprotective, and may slow the onset or progression of the 
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disease (6Wahner et al., 2007), recent trials of the impact of NSAIDs on PD 
progression have not produced positive results (Bornebroek M. 2007). The 
mechanisms by which NSAIDs offer protection to PD patients are still elusive. It is 
possible that they reduce the inflammatory response in the brain.  
Although current anti-inflammatory drugs are of great value in the treatment 
of PD, the disadvantage is that the use of them is systemic and they do not distinguish 
between pathological immune responses and protective immune responses. Moreover, 
they have to be given at quite high dosage compared to regional therapy (Klegeris and 
McGeer, 2005). The recently developed stem cell transplantation may overcome this 
shortcoming because of the chemotaxis lead by chemokine-receptor interactions 
between the local degenerated cells and the transplanted stem cells.  
4.2. Stem cell transplantation 
Stem cells are defined by their capability for self-renewal and multipotent 
differentiation. On the basis of these properties, the hope of cell replacement as a 
possible strategy for the CNS is worth considering because stem cells could 
differentiate into neural cells. Neural stem cells would be good candidate for cell 
replacement in neurodegenerative disease, however, the limited sources for in vitro 
expansion has made it difficult to use broadly in the future clinical study. 
Mesenchymal stem cells (MSCs) represent one of the most accessible 
sources of multipotent stem cells for therapeutic use. The ease with which they are 
harvested (i.e as a simple marrow aspirate) and the ease of their culture and expansion 
in vitro make MSCs a good candidate for cell therapy. 
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4.2.1. Historical discovery of MSCs 
Bone marrow contains precursors for hematopoietic and stem-like cells, for 
a variety of non-hematopoietic tissues. The precursors for non-hematopoietic tissues 
were initially referred to as plastic-adherent cells or colony-forming-units fibroblasts 
because of their ability to adhere to culture dishes and form fibroblast-like colonies 
(Friedenstein et al., 1974; Piersma et al., 1985). In addition, these cells have been 
referred to as mesenchymal stem cells (MSCs) or mesenchymal progenitor cells for 
possessing the capability to differentiate into multiple nonhematopoietic cells (Caplan, 
1991). Moreover, they have been referred to as marrow stromal cells (MSCs), as they 
are originated from the supporting tissues in the bone marrow and can act as feeder 
layers for the growth of hematopoietic stem cells in in vitro culture (Prockop, 1997). 
MSCs have been identified in bone marrows from human, primates and rodents 
(Rickard et al., 1994; Phinney et al., 1999; Javazon et al., 2001). 
4.2.2. Biological characteristics of MSCs 
Although MSCs have been broadly investigated, at present no specific 
marker or combination of markers has been identified to specifically define MSCs. 
However, phenotypically, in vitro expanded MSCs express a number of nonspecific 
markers, including CD105 (SH2 or endoglin), CD73 (SH3 or SH4), CD90, CD166, 
CD44, and CD29 (Pittenger, 2008) while negative for most haematopoietic and 
endothelial cell markers (CD45, CD34, CD11a, CD235a, HLA-DR, CD144) 
(Dvorakova et al., 2008; Pittenger, 2008).   
4.2.3. Proliferation of MSCs 
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Stem cells are defined as a cell population that are capable of sustained 
replication and possess multipotent differentiation potential. It has been demonstrated 
that MSCs from rabbit can be amplified to 20 or 30 folds in culture and still 
synthesize bone after transplantation in diffusion chambers in vivo (Friedenstein et al., 
1987). A recent study also reported that MSCs derived from human bone marrow 
aspirates were able to undergo 38 ± 4 doublings in vitro (Ferrari et al., 1998). 
4.2.4. Multipotent differentiation of MSCs 
MSCs isolated by their adherence to tissue culture glass and plastic are 
multipotential, in that they can differentiate into osteoblasts, adipocytes and 
chondrocytes and subsequently they were shown to differentiate into myoblasts and 
myotubes (Piersma et al., 1985; Clark and Keating, 1995; Wakitani et al., 1995; 
Ferrari et al., 1998; Pereira et al., 1998; Makino et al., 1999).  
In addition to osteoblasts, chondrocytes and adipocytes, MSCs have also 
been shown to transdifferentiate into neurons and glial cells both in vivo and in vitro 
(Azizi et al., 1998; Sanchez-Ramos et al., 2000; Woodbury et al., 2000). In the 
classical review of developmental biology, organisms are shaped by cellular 
differentiation that is unidirectional, with cells never switching lineages. This concept 
has been challenged over the past few years by reports suggesting that stem cells from 
various tissues might be more plastic than previously anticipated, with the ability to 
generate cells of lineages thought of as unrelated (Anderson et al., 2001; Clarke and 
Frisen, 2001). This suggests that cells from one lineage can be reprogrammed 
(transdifferentiated) to change into a completely distinct phenotype of cells from 
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another lineage.  
Although various methods for inducing MSCs into neuron-like cells have 
been reported in vitro and the systemic injection of MSCs in mice with brain injury 
had positive effects on injury repair, incompatible genetic background such as 
neurofilament light chain deficiency (NFL-/-) and the low transdifferentiation rate 
may limit its employment in therapeutic intervention (Chao et al., 2007). Moreover, it 
is also possible that transdifferentiation of MSCs into neural cells in vitro could be 
due to experimental manipulation as extensive passaging in vitro could select for cells 
with traits not normally present in the starting population. 
4.2.5. Immune modulatory effect of MSCs 
Even though transplantation of MSCs may be promising for cell 
replacement therapy in neurodegenerative diseases, their immunomodulatory 
function that contributes to the survival of neurons is not well understood. Recent 
studies have shown that in vitro expanded MSCs possess the unique ability to 
suppress immune responses, both in vitro and in vivo. Making use of multiple 
pathways, in vitro expanded MSCs have been shown to suppress the function of a 
broad range of immune cells, including T cells, B cells, NK cells and 
antigen-presenting cells (Fig. 4) and thus may have therapeutic effect in autoimmune 
diseases (El-Badri et al., 2004). However, immune modulation of MSCs on the 
activated microglia, one of the innate immune families, has not been well 
documented.  
4.2.6. Mechanisms of immune modulation of MSCs 
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The mechanisms by which in vitro-expanded MSCs mediate their 
immunosuppression have only recently started to be elucidated. Soluble factors 
secreted by MSCs, or by immune cells in response to MSCs, play a major role in 
MSC-mediated immune suppression.  
MSCs express various cytokines which are known to play roles in 
haematopoiesis, including IL-6 and IL-7, leukaemia inhibitory factor (LIF), stem cell 
factor (SCF), granulocyte and macrophage colony-stimulating factors (Haynesworth 
et al., 1996; Dormady et al., 2001). Some of the cytokines (IL-6, LIF, SCF, 
granulocyte and macrophage colony-stimulating factors) have been reported to 
influence the differentiation of cells derived from the bone marrow stroma through 
target-cell receptors which use glycoprotein-130-associated signal transduction 
pathways (Taguchi et al., 1998). These findings show that MSCs have a distinct 
cytokine expression profile consistent with the ability to support haematopoiesis and 
also supply autocrine, paracrine, and juxtacrine factors that influence the cells of the 
bone marrow microenvironment itself (Haynesworth et al., 1996). 
New studies showed that multiple immunosuppressive factors can be 
released by MSCs and the nature of these factors varies depending on the different 
stimuli received by MSCs (e.g. allogeneic determinants, membrane-bound proteins, 
mitogens and cytokines). Soluble factors such as hepatocyte growth factor, 
prostaglandin E2 (PGE2), transforming growth factor (TGF) β1, indoleamine 
2,3-dioxygenase (IDO), nitric oxide (NO) and IL-10 have been reported to be 
involved in the immune modulatory effect of MSCs, while other factors remain 
INTRODUCTION                                                   28 
unknown (Tse, et al., 2003; Djouad et al., 2003; Aggarwal and Pittenger, 2005; 
Beyth et al., 2005; Sato et al., 2006). Some studies reported that contact-dependent 
mechanisms might also be implicated, including the expression of the 
immunomodulatory protein B7 homolog-1 (B7H1) on MSCs (Romieu-Mourez et al., 
2007).  
Cytokines play an important role in the regulation of MSC-mediated 
immunosuppression. It has been reported that TNF-α can enhance by as much as 
100-fold the production of immunosuppressive prostaglandins by MSCs (Aggarwal 
and Pittenger, 2005). IFN-γ is another crucial cytokine that regulates MSCs’ immune 
functions. Many reports have indicated that IFN-γ plays an active role in the 
immunosuppressive effect mediated by MSCs (Ryan et al., 2007; Polchert et al., 
2008). IFN-γ can induce MSCs to release prostaglandins and IDO (Jones et al., 
2007), which may suppress lymphocyte proliferation.  
4.2.7. Systemic administration of MSCs 
Recently it has been reported that intravenous transplantation of MSCs has 
a therapeutic effect on the experimental autoimmune encephalomyelitis (EAE), a 
model of human multiple sclerosis, through inducing peripheral T cell tolerance 
against the pathogenic stimuli (Zappia et al., 2005).  
Current anti-inflammation medicines do not distinguish between 
pathological immune responses and protective immune responses. Systemic immune 
modulation may therefore also depress host immune responses against infections 
caused by bacteria, fungi, and viruses. This is particularly important in stem cell 
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transplantation for patients with autoimmune diseases, since in these patients the 
immune system is already compromised. It is therefore of great importance to 
critically examine the effects of immunosuppression induced by MSCs and to 
compare with immunosuppressive agents currently used in the clinic. The 
immunosuppressive effects of MSCs are antigen nonspecific and independent of 
MHC expression: similar inhibitory effects being reported with MSCs that were 
autologous, allogeneic, or xenogeneic to the responder cells (Li et al., 2005; 
Moadsiri et al., 2006; Portmann-Lanz et al., 2006). However, MSCs have also been 
demonstrated to express series of chemokines receptors which could interact with the 
chemokines released by the damaged cells at sites of injury (Ji et al., 2004) and may 
therefore provide site-specific and local immunosuppression. This may serve as a 










Figure 4. Immunomodulatory effects of MSCs. CTL indicates cytotoxic T cell; HGF, 
hepatocyte growth factor; IDO, indoleamine 2,3-dioxygenase; PGE2, prostaglandin 
E2; and TGF-ß, transforming growth factor ß.(Nauta and Fibbe, 2007). 
 
4.2.8. Therapeutic potential of MSCs to treat CNS diseases and injuries 
Dueing to the simple harvesting, culturing and expansion procedures, MSCs 
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represent one of the most accessible sources of multipotent stem cells for therapeutic 
use in the treatment of CNS diseases   
The potential of human MSCs to engraft and differentiate in the CNS has 
been tested by direct infusion into the basal ganglia of adult rats (Azizi et al., 1998). 
Without invoking immune response, the infused cells integrated and migrated along 
known pathways in a manner that was similar to the integration and migration of 
neural stem cells. Also, there was no evidence that the infused cells differentiate into 
neural cells in the brain (Azizi et al., 1998). A later study also showed that murine 
MSCs infused into the periventricular region of the brain of newborn mice integrated 
and migrated throughout the forebrain and cerebellum without destruction to the host 
brain architecture and some of the infused cells differentiated into astrocytes (Kopen 
et al., 1999). Another report also suggests that transplanted MSCs migrate to the 
injury sites through a chemokine-receptor interaction (Ji et al., 2004). These results 
suggest that MSCs are potentially useful as vectors for treating CNS diseases. 
Transplantation of MSCs has been addressed in a number of animal models 
of CNS diseases and injuries including stroke (Li et al., 2002), traumatic brain injury 
(Mahmood et al., 2001, 2002, 2003), Parkinson’s disease (Li et al., 2001), and 
demyelinated spinal cord (Akiyama et al., 2002). It has been shown that the 
transplanted MSCs promote the functions of the impaired brains in these models. The 
evidence has suggested their therapeutic potential to regenerate or protect neural cells 
in the injured or diseased brain (Prockop et al., 2000; Shintani et al., 2007).  
Despite the systemic injection of MSCs into mice with brain injury had 
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positive effects on injury repair, incompatible genetic background and the low 
transdifferentiation rate may limit its employment in therapeutic intervention for cell 
replacement (Chao et al., 2007). Other mechanisms have to be exploited to explain the 
therapeutic effect of MSCs transplantation. Here, the author speculates that the 
therapeutic and beneficial effects in vivo of cultured MSCs are mostly due to an 
immune modulatory effect on immune cells associated with a pro-survival trophic 
effect on injured cells. 
 
5. Hypothesis 
        Based on the above review, the author hypothesized that: i) the integrity of 
tight junction of BBB is compromised in the SNc of MPTP-treated mice; ii) 
peripheral inflammatory factors such as MBL and NK cells may go through the 
compromised BBB and participate in the pathogenesis of PD; and iii) MSC 
transplantation could rescue dopaminergic neurons from MPTP toxicity through 
repairing the compromised BBB, suppressing the immune reactivity or directly 
interact with dopaminergic neurons in the SNc.  
In line with these hypotheses, the author employed the MPTP-treated PD 
models and investigated the involvement of blood-brain barrier impairment and 
peripheral inflammatory factors infiltration in the pathogenesis of PD. The author also 
tested whether systemically administered MSCs cross the compromised blood-brain 
barrier, survive, differentiate in the substantia nigra, modulate the local immune 
response and protect dopaminergic neurons from the toxicity of MPTP in mice. 
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6. Aims of the present study 
Neurodegenerative disorders including PD are very common in aged people 
and influence the life quality of the patients severely. Understanding the mechanisms 
controlling neurodegeneration could lead to the development of therapeutic 
approaches to interfere with neurodegenerative processes. MPTP-treated mouse 
serves as a good PD model to gain insight into the mechanisms of progressive 
dopaminergic neuronal injury and degeneration.  
6.1. Analysis of the dopaminergic neuron degeneration in the SNc after 
MPTP-treatment 
        The degeneration of dopaminergic neurons after MPTP-treatment in the 
SNc of mice has been well documented (Kolata, 1983; Burns et al., 1983; Chiueh et 
al., 1984; Heikkila et al., 1984). However, the mechanisms underlying the 
degeneration remain poorly understood. In an attempt to address the pathogensis in 
the degeneration of dopaminergic neurons in the SNc after MPTP-treatment, the 
present study aims to examine the activation of microglia, the functional changes of 
BBB and the involvement of peripheral inflammatory factors. 
6.1.1. Study of pathological changes of the dopaminergic neurons in the SNc after 
MPTP-treatment 
To examine the morphological and quantative changes of dopaminergic 
neurons in the SNc, serial coronal sections of the midbrains of mice after 
MPTP-treatment will be stained by tyrosine hydroxylase (TH) histochemistry staining 
method. The number of dopaminergic neurons in the SNc and ventral tegmental area 
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(VTA) was quantified and statistically analyzed. This will provide evidence indicating 
neurodegeneration in the SNc after MPTP-treatment. 
6.1.2. Study of the activation of microglial cells in the SNc after MPTP-treatment 
Immunohistochemistry method will be carried out with antibodies CD11b 
and MHC II to investigate the activation of microglial cells in the SNc. The number of 
microglial cells in the SNc was quantified and statistically analyzed. This will provide 
evidence of microglial activation in the SNc after MPTP-treatment. 
6.1.3. Study of the changes in integrity of blood-brain barrier in the SNc after 
MPTP-treatment 
        The expressions of some tight junction molecules such as claudin 1, claudin 
5 and occludin will be examined in the SNc after MPTP treatment using immuno-EM 
and Western blot analysis. The integrity of BBB will be tested with intravenous 
injection of FITC-albumin. This information will provide evidence indicating the 
involvement of BBB compromise in the pathogenesis of MPTP-induced PD. 
6.1.4. Study of the peripheral inflammatory response and infiltration in the SNc after 
MPTP-treatment 
        The expression profile of mannose binding lectin acute (MBLA) and 
chronic (MBLC) in the liver tissue will be studied using RT-PCR and Western blot 
analysis. The infiltration of MBLA, MBLC and natural killer (NK) cells in the SNc 
will be investigated using MBLA, MBLC and NKG2D antibodies, respectively. This 
information will help elucidate the functional roles of peripheral inflammatory factors, 
such as MBLA, MBLC and NK cells, in the pathogenesis of MPTP-induced PD. 
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6.2.Therapeutic effect analysis of MSC transplantation in the MPTP-treated 
mice 
    As an inflammatory process in the SNc plays an important role in the 
pathogenesis of Parkinson’s disease, suppression of microglia-mediated inflammation 
has been considered as an important strategy in the therapy of PD. Several 
anti-inflammatory drugs have been shown to repress the microglial activation and to 
exert neuroprotective effects. However, these drugs do not specifically target 
microglial cells in the SNc and therefore, exhibit potential systemic side effects. 
MSCs have recently been reported to have an immune modulatory effect both in vitro 
and in vivo (El-Badri et al., 2004; Zappia et al., 2005; Ryan et al., 2007; Polchert et al., 
2008). And after transplantation, the MSCs migrate to the target region through a 
chemokine- chemokine receptor interaction released by MSCs and the damaged local 
cells. Identification of the effect of MSC transplantation on the damaged 
dopaminergic neurons and inflammation process is of great importance for 
understanding the MSC-mediated cell therapy for PD as well as other 
neurodegenerative disorders. The aim of this study is to examine the restoration of 
BBB and immune suppression after MSC transplantation in the MPTP-treated mice, 
which may provide alternative explanations to the therapeutic effect of MSC 
transplantation on PD.  
6.2.1. Rescue of the dopaminergic neurons in the SNc of MPTP-treated mice after 
MSC transplantation 
To examine the morphological and quantative changes of dopaminergic 
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neurons in the SNc after MSCs transplantation, serial coronal sections of the 
midbrains of mice after MPTP+MSCs-treatment will be stained by tyrosine 
hydroxylase (TH) histochemistry staining method. The number of dopaminergic 
neurons in the SNc and VTA was quantified and statistically analyzed. This will 
provide evidence indicating dopaminergic neuronal protection or rescue in the SNc 
after MSC transplantation in the MPTP-treated mice. 
6.2.2. Recruitment and destination of MSCs in the SNc after transplantation 
        Double-labeling of CFDA SE pre-labeled MSCs with TH (for dopaminergic 
neurons), MHC II (for activated microglia/monocytes) and GFAP (astrocytes) 
antibodies will be carried out using confocal microscopy. The results will provide the 
information of the recruitment and destination of transplanted MSCs in the SNc in the 
MPTP-treated mice. 
6.2.3. Suppression of microglia activation in the SNc of MPTP-treated mice after 
MSC transplantation 
Immunohistochemistry method will be carried out with antibodies CD11b 
and MHC II to investigate the alteration in activation of microglial cells in the SNc 
after MSC transplantation. The number of microglial cells in the SNc was quantified 
and statistically analyzed. This will provide evidence indicating the suppression of 
microglial activation in the SNc after MSC transplantation in the MPTP-treated mice. 
6.2.4. Restoration of blood-brain barrier integrity in the SNc of MPTP-treated mice 
after MSC transplantation 
The expressions of tight junction molecules such as claudin 1, claudin 5 and 
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occludin will be examined in the SNc after MSC transplantation in the MPTP-treated 
mice using immuno-EM and Western blot analysis. The integrity of BBB will be 
tested with intravenous injection of FITC-albumin. This information will provide 
evidence indicating that MSC transplantation may protect dopaminergic neurons from 
peripheral factors by restoring the integrity of BBB in the MPTP-treated mice. 
6.2.5. Suppression of peripheral inflammation in the MPTP-treated mice after MSC 
transplantation 
After MSC transplantation in the MPTP-treated mice, the expression 
profiles of MBLA and MBLC in the liver tissue will be studied using RT-PCR and 
Western blot analysis. The infiltration of MBLA, MBLC and NK cells in the SNc will 
be investigated using MBLA, MBLC and NKG2D antibodies, respectively. This 
information will help elucidate that the neuronal protective effect of MSC 
transplantation may be due to the suppression of peripheral inflammatory factors, 
such as MBLA, MBLC and NK cells, in the MPTP-treated mice. 
6.2.6. The expressions of chemockines by MSCs as the potential mechanism of their 
immune suppressive effect 
        RT-PCR and ELISA EMSA methods will be carried out to investigate the 
expressions of TGFβ1 and IL-6 at the mRNA and protein levels in the MSCs both in 
vivo and in vitro. EMSA method will be used to investigate the NFκB signaling 
pathway underlying the release of TGFβ1 and IL-6 in vitro. This will provide clues 
showing the mechanism of the immune modulating effect of MSCs. 
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6.3. The effect of NFL-/- on the MSC proliferation and differentiation  
    In addition to the contribution of inflammation to the pathogenesis of PD and 
therapeutic effect of MSC transplantation, studies also documented that gene 
mutations play an important role in the development of PD (Waragai et al., 2006; 
Periquet et al., 2007). And the autologous MSCs may carry the same genetic 
deficiency, which may result in a failure of cell replacement. Thus it is important to 
investigate whether the phenotype of a gene deficiency will be carried on by MSCs 
when the MSCs differentiate into neurons. The MSCs will be isolated from the mice 
with targeted disruption of neurofilament light subunit (NFL-/-), whose neurons 
contain the perikaryal protein aggregations. 
 Another aim of this study is to investigate the effect of neurofilament light 
subunit (NFL) deficiency on the proliferation and differentiation of MSCs.  
        Cell proliferation colorimetric assay kit will be used to investigate the 
proliferation of NFL-/-MSCs. Retinoic acid (RA) will be employed to induce MSCs 
differentiation into neuronal cells. Immunohistochemistry method with NFH (for 
neurons), MAP-2 (for neurons), NeuN (for neurons), nestin (for neural precursor 
cells), O4 (for oligodendrocytes) and GFAP (astrocytes) antibodies will be used to 
investigate the neuronal differentiation of NFL-/- MSCs after RA-treatment. RT-PCR 
and Western blot analysis methods will be carried out to test the expressions of NFL 
and NFH at mRNA or protein levels of NFL-/-MSCs after RA-treatment.










MATERIALS AND METHODS 
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1. Animal 
A total of 211 adult (8-12 weeks old) male mice (C57BL6/J strain) 
weighing about 20-25g were used in the present study: 180 adult mice were 
used for Parkinson’s disease models; 31 for MSCs culture. The mice were 
purchased from the Laboratory Animals Centre/Centre for Animal Resources 
(CARE), Singapore.  
Another 8 adult (8-12 weeks old) NFL-/- mice (C57BL6/J 
background) weighing about 20-25g were used for NFL-/- MSCs culture. The 
NFL-/-mice were kind gift from Dr. JP Julien (Laval University, Canada). 
The mice were housed in clean cages in a temperature-controlled 
room with 12 hour shift in light/dark cycle and free access to food and water. 
 
2. Anaesthesia 
Prior to surgery, perfusion or harvesting of tissue samples or cells, all 
animals were deeply anaesthetized by an intraperitoneal injection of 7% chloral 
hydrate (5 ml/kg body weight) or by an intraperitoneal injection of Nembutal 
(30mg/1kg body weight). After 10-15 minutes, one of the foot pads of the 
animals was pinched with a pair of toothed forceps to ensure the animals were 
under full anaesthesia. All procedures involving animals were approved by the 
Institutional Animal Care and Use Committee (IACUC), National University of 
Singapore. 
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3. Establishment of PD models and treatment groups 
3.1. Experiment groups 
To study the pathogenesis and therapeutic effects of MSC 
transplantation in the PD model, four treatment groups were observed, 
including  (1) saline (IP) (n=36), (2) MPTP (IP) (n=48), (3) MPTP (IP) plus 
saline (IV) (n=48), and (4) MPTP (IP) plus MSCs (IV) (n=48).  
3.2. MPTP administration 
MPTP-induced PD model was established according to previous 
report (Wu DC et al., 2002). Briefly, MPTP (Sigma, St. Louis, MO, USA) was 
administered in a series of four intraperitoneal injections of 20 mg/kg (free base) 
at 2 hour intervals for a total administration of 80 mg/kg. This has been 
confirmed to lead to about 60% loss of nigrostriatal neurons, as determined by 
unbiased stereological techniques for both TH and Nissl substance staining and 
an 80–90% depletion of striatal dopamine levels (Jackson-Lewis et al., 1995; 
Jakowec and Petzinger, 2004). Nigrostriatal cell loss was complete at day 3 
after MPTP administration as determined by counting the remaining TH 
immunoreactive cells in the SNc. 
3.3. Tail vein injection of FITC-albumin 
FITC-albumin (10 mg/ml, Sigma-Aldrich, USA) was injected at a 
volumn of 100ul/mouse through the tail vein. Animals were decapitated 20mins 
after injection and the brains were immersed in 4%PF for frozen section. 
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2% paraformaldehyde (PF): 
PF (Sigma, USA)                               20g 
0.1M phosphate buffer (pH 7.4)                   1000ml 
4% PF: 
PF                                           40g 
0.1M phosphate buffer (pH 7.4)                   1000ml 
The pH was adjusted to 7.4 by adding 1N HCl solution. 
        2%PLP: 
          L-Lysine                                      13.7g 
          D.H2O                                        375ml 
          0.1M Solution ‘B’ 
          (178gNa2HPO4.2H2O in 10 litres Deionised H2O)     125ml 
0.1M Solution ‘A’ 
          (69gNaH2PO4. H2O in 5 litres Deionised H2O)       ±250ml 
PB (Add approx 1 volume of ‘A’ to 3 volumes of ‘B’ till pH 7.4) 
8% PF                                 20gPF/250ml H2O 
1N NaOH                                2.5-7.5drops 
Sodium m-perodate                        2.14g 
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4% PF + 0.1% glutaraldehyde (GA) in 0.1M PB (pH 7.4): 
PF                                            4g 
25% GA (TAAB Laboratories, England, UK)          0.4ml 
0.1M PB (pH 7.4)                                99.6ml 
 
2% PF + 3% GA in 0.1M PB (pH 7.4): 
PF                                            2g 
25% GA                                       12ml 




All fixatives used in the present study were freshly prepared before 
use. The paraformaldehyde solution was prepared by heating paraformaldehyde 




A midline incision of the skin from the level of the suprasternal notch 
to the level above the symphysis pubis was made. The incision, made through 
the skin and muscles of the anterior abdominal wall, was extended bilaterally 
along the subcostal margins to expose the sternum and diaphragm. The latter 
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was then cut along the subcostal margin to fully expose the heart. Care was 
taken during this process not to damage the lungs. The pericardium was then 
slit with a pair of fine scissors to fully expose the heart. The perfusion was 
carried out under gravity with the reservoirs containing the fixative and 
Ringer’s solution fixed at a height of about 100 cm above the animal. Perfusion 
was initiated whereby a cannula with some Ringer’s solution dripping slowly 
from its tip was inserted into the left ventricle and was immediately followed 
by slitting a portion of the right atrium to let out the blood, and subsequently 
the perfusate. Once the cannula was secured in place, the flow of the Ringer’s 
solution was turned to full pressure by means of a three-way tap. A total of 
50-70 ml of Ringer’s solution at room temperature was allowed to flush the 
vascular system until the lungs and liver were cleared of blood. A total of about 
200 ml of the fixative (2% or 4% PF or 2% PLP) at room temperature was then 
administered. 
4.2. Tissue preparations 
Preparation of gelatinized and salinized slides 
Materials 
5% gelatin solution: 
Gelatin 1.5mg 
Chrome Alum 0.15g 
Distilled water 100ml 
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2% silane solution 
Silane 2ml 
Absolute alcohol 98ml 
 
Procedure 
Slides were first dipped in the acid solution (400ml of 98% sulfuric 
acid mixed with 1 tea spoon of potassium dichromate) for 2min, and then 
washed by running tap water for 10min. The slides were rinsed with distilled 
water and then baked in an oven at 80ºC overnight for drying. 
Gelatinized slides: The following day, dried slides were dipped in the 
gelatin solution and then were hung to dry with the clips. Gelatinized slides 
were kept in an oven at 37ºC for histological or immunohistochemical studies.  
Salinized slides: The dried slides were dipped into absolute alcohol 
for 2 min, then in 2% saline solution for 5-10min, and rinsed in absolute 
alcohol followed by deionised water. The slides were dried in an oven at 60ºC 
and kept at 37ºC for histological or immunohistochemical studies. 
 
Preparation of frozen sections 
The midbrains were dissected and post-fixed with 2% or 4% PF or 
2% PLP for additional 2 hours. The tissues were subsequently transferred to 
0.1M phosphate buffer (pH7.4) containing 20-30% sucrose and kept overnight 
at 4°C. The tissue samples were mounted on a metal chuck using Lipshaw M-1 
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embedding matrix (Pittsburgh, USA) and rapidly frozen by quenching in liquid 
nitrogen. Transverse sections of brainstems (20μm thickness) were cut using a 
cryostat (Leica CM 3050). The sections were subsequently mounted on 
gelatinized or salinized slides and allowed to dry at room temperature for 1 
hour.  
 
4.3. Nissl (Cresyl Fast Violet-CFV) staining 
Materials 
0.25 % CFV stock solution: 
Cresyl Fast Violet (GURR’S, UK)                   0.25g 
Deionised water                                 100ml 
 
CFV staining solution: 
One part of 0.25 % CFV stock solution 
Two parts of 0.2 N acetic acid 
Procedure 
Frozen coronal sections (20μm) of the midbrains were cut 3 and 7 
days after MPTP-treatment and every 6th section was then were immersed in 
CFV staining solution at 60 °C for 5-10 minutes, followed by differentiation in 
70% ethanol. The sections were dehydrated in an ascending series of ethanol 
and passed through xylene before being coverslipped with Permount as 
mountant. They were then viewed under a Nikon light microscope. After Nissl 
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staining, the neurons in the SNc of four sections for each mouse (three mice for 
each group) were counted, averaged and analyzed quantitatively using 
Student’s t-test. 
 
5. Primary culture of MSCs 
Materials 
Complete culturing medium: 
Fetal bovine serum (FBS) (Sigma)                     75ml 
Antibiotic antimycotic solution (100×) (Sigma)           5ml 
Dulbecco’s Modified Eagle Medium (DMEM, Gibco, USA) 420ml 
Complete culturing medium comprises 15% FBS, 2mM L-glutamine and 
100U/ml penicillin, 100μg/ml streptomycin and 0.25μg/ml amphotericin B. 
Other materials: 
70μm cell strainer (BD Bioscience Discovery Labware, USA); 75cm2 
flask (Iwaki, Japan); Falcon tubes (Falcon, USA); Petridishes and 21-gauge 




MSCs were isolated as previously described with some modifications 
(Digirolamo et al., 1999). Briefly, the whole bone marrow plugs were obtained 
by flushing the bone marrow cavity of the femurs and tibiae of adult C57BL6/J 
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mice with a 27- gauge syringe filled with DMEM supplemented with 15% fetal 
bovine serum, 2mM Lglutamine and 100U/ml penicillin, 100μg/ml 
streptomycin and 0.25μg/ml amphotericin B. Cells were passed through 70μm 
cell strainer to remove remaining clumps of tissue, then plated in a 75cm2 flask 
and incubated at 37°C in a humidified atmosphere of 95% air and 5% CO2. The 
first medium change was done within 24h to remove the non-adherent 
hematopoietic lineage cells, and the adherent cells were continuously grown to 
90% confluence. 
Cell dissociation technique 
Materials 
Digestion solution (0.25% trpsin/EDTA): 
0.5% trypsin-EDTA solution (Sigma)                    1ml 
Sterile PBS (pH7.4) (NUMI, Singapore)                  1ml 
 
Procedure 
For further expanding and processing, MSCs were washed with 5ml 
of sterile PBS (pH 7.4) twice and incubated with 2ml of 0.25% trypsin/1mM 
EDTA for 5min at 37°C. The reaction was stopped by adding 10ml of complete 
medium. The detached cell solution was transferred to a sterile Falcon tube and 
centrifuged at 1200g for 3min. The supernatant was removed and the cell pellet 
was resuspended in 10ml of complete culturing medium in 75cm2 flasks for 
passage or processed for other experiments. 
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5.1. In vitro differentiation assay 
Neuronal differentiation 
Materials 
       Mitogenic Solution (20ng/ml EGF): 
          EGF (Sigma, USA)                              2ng 
          FBS (NUMI, Singapore)                          10ml 
          Antibiotic (100x, NUMI, Singapore)                 1ml 
DMEM solution (NUMI, Singapore)                 89ml 
 
       Neuronal differentiation solution (30μM RA): 
Trans-retinoic acid (RA, Sigma, USA)               3μmol 
FBS (NUMI, Singapore)                          10ml 
          Antibiotic (100x, NUMI, Singapore)                 1ml 
DMEM solution (NUMI, Singapore)                 89ml 
 
Procedure 
MSCs at 80% confluence were trypsinized and then sub-cultured in 
6-well plates at a density of 1x105 cells/well with or without coverslips coated 
with poly-L-lysine. Epidermal growth factor (EGF, 20ng/ml, Sigma, USA) was 
added to culture medium for 24 hours before it was replaced with trans-retinoic 
acid (RA, 30μM, Sigma, USA) containing media. The cultures were re-fed with 
fresh medium containing 30μM RA every 3 or 4 days. At 10 days after RA 
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treatment, cells were studied by immunocytochemistry, RT-PCR, and Western 
blot. 
 
5.2. Cell proliferation assay 
Material 
CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit 
(MTS, Cat. No. G3580; Promega, USA) 
Procedure 
MSCs were seeded on 96-well plates at a density of 1x104/ml in 100µl 
of DMEM per well. After 1-7 days of incubation, the medium in each well was 
removed and 100µl of fresh complete medium containing 20µl of MTS reagent 
were added into each well containing MSCs cultures. The cultures were 
incubated for 4 h at 37ºC in dark with a humidified atmosphere of 95% air and 
5% CO2 before the absorbance at 490nm was measured using a microplate 
reader (GENios, Tecan, Switzerland). The absorbance is directly proportional 
to the number of MSCs in each well at each time course. The relative increase 
of the number of MSCs was represented by the ratio of the absorbance to the 
control absorbance. The results are expressed as mean ± SD of the ratios. 
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5.3. In vitro analysis of cytokine release of MSCs  
5.3.1. Measurement of TGF-β1 and IL-6 by enzyme-linked immunosorbent 
assay (ELISA) 
Materials  
Lipopolysacharide (LPS) solution (1μg/ml): 
LPS (Sigma-Aldrich, USA)                          10μg 
FBS (NUMI, Singapore)                            1ml 
          Antibiotics (100x, NUMI, Singapore)                  0.1ml 
          DMEM solution (NUMI, Singapore)                   8.9ml 
TGF-β1 ELISA kit (R&D, USA) 
IL-6 ELISA kit (R&D, USA) 
Costar enzyme immunoassay/radioimmunoassay (EIA/RIA) 3590 
plates 
ELISA plate reader (Molecular Devices, USA) 
Procedure 
As previously described (Amoudruz et al, 2006), the cell free 
supernatants with or without treatment with the LPS (1μg/ml) were used for 
measuring the TGF-β1 and IL-6 protein using TGF-β1 and IL-6 ELISA kit 
(R&D, USA). Costar enzyme immunoassay/radioimmunoassay (EIA/RIA) 
3590 plates were coated overnight at 4°C with 50 µl/well of capture mAbs 
TGF-β1 and IL-6. After washing, the plates were incubated with 100 µl/well of 
0.5% bovine serum albumin (BSA). 50 µl of the culture supernatants from the 
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stimulation procedure or standard dilutions were added to duplicate wells and 
incubated. The standards (R&D Systems, USA) used were TGF-β1 (Part 
841389) and IL-6 (Part 840173). After washing, biotinylated monoclonal 
antibodies (1 µg/ml, 50µl/well) specific to either TGF-β1 or IL-6 were added. 
Color was developed at room temperature with p-nitrophenyl phosphate 
(Sigma Diagnostics, St Louis, MO), and the absorbance was measured at 
405 nm with a precision microplate reader (SOFTmax alias, Molecular Devices, 
kinetic microplate reader, Sunnyvale, CA). To avoid differences in results due 





LPS solution (1μg/ml) 
Rabbit-anti NFκB antibody (Santa Cruz Biotechnology, 
Inc)  
Cy3-conjugated anti-rabbit secondary antibody (Millipore, 
USA) 
Procedure 
MSCs were subcultured on poly-L-lysine coated slides in a 6-well 
plate at a density of 1 × 105 cells/well. The cells were pretreated for 30 minutes 
with 1g/ml LPS in DMEM culture medium together with 10% FBS, and then 
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fixed with 4% PF for 10 minutes. Immunofluorescence was carried out as 
above description with rabbit-anti NFκB antibody (Santa Cruz Biotechnology, 
Inc) and Cy3-conjugated anti-rabbit secondary antibody, and then examined 
under an Olympus confocal microscope (LSM 510 Zeiss, Japan).  
5.3.3. Electrophoretic mobility shift assay (EMSA) 
Materials 
         LPS solution (1μg/ml) 
         EMSA “gel-shift” kits (Panomics, Singapore) 
Procedure 
MSCs subcultured in 75mm flasks with or without treatment with the 
LPS (1μg/ml) were used for nuclear protein extraction and NF-κB nuclear 
translocation analysis. Nuclear protein extracts were obtained using a nuclear 
extract kit (Panomics, Singapore), according to the manufacturer's instructions. 
Gel shift assays were performed using EMSA “gel-shift” kits (Panomics, 
Singapore). Briefly, biotin-labeled double stranded NF-κB oligonucleotides 
were incubated with or without unlabeled competitor oligonucleotides in the 
presence of 5 µg nuclear extracts and binding buffer (50 mM KCl, 1 mM DTT, 
5% Glycerol, 0.1% Nonidet P-40, 10 mM MgCl2; pH 7.5) at room temperature 
for 30 minutes. Resulting products were resolved on 6% non-denaturing 
polyacrylamide gels, transferred to PVDF membranes, and visualized with a 
chemiluminiscent detection kit (Pierce, Rockford, IL) according to the 
manufacturer's instructions. 
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5.4. Labelling of MSCs with 5-(and-6)-carboxyfluorescein diacetate 
succinimidyl ester (CFDA-SE) 
Materials 
10mM labelling stock solution: 
CFDA-SE (Molecular Probes, USA)                 5.57mg 
DMSO                                        1ml 
10μM labelling solution: 
10mM labeling stock solution                      10μl 
PBS                                           10ml 
Procedure 
MSCs were washed with three volumes of PBS. The cells were 
incubated in 10ml of 10μM CFDA-SE in PBS for 30min at 37°C and then 
replaced with complete culture medium. The positive labeling was examined 





Di-sodium hydrogen phosphate heptahydrate            13.3g 
Sodium chloride                                   8.5g 
Distilled water to make up to                         1000ml 
The solution was adjusted to pH 7.4 with 1N hydrochloric acid (HCl). 
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PBS containing 0.1% Triton-X 100 (PBS-TX): 
Triton-X 100                                       1ml 
PBS                                             1000ml 
0.05M Tris buffered saline (TBS; pH 7.6): 
Tris base (Trihydroxymethylaminomethane)             6g 
Sodium chloride                                   8g 
Distilled water                                    1000ml 
pH was adjusted with 1N HCl 
0.1% ammonium nickel sulphate TBS (pH 7.6): 
Ammonium nickel sulphate                          1g 
TBS                                             1000ml 
3,3’ diaminobenzidine tetrahydrochloride (DAB) solution: 
DAB (Sigma, USA)                                 50mg 
30% hydrogen peroxide                              33μl 
TBS                                            100ml 
Procedure 
Immunostaining was performed on the frozen sections of the 
midbrains and the cells plated on polylysine-coated coverslips. The slides and 
coverslips were rinsed for 30min in 0.1% PBS-TX solution. Sections or cells 
were then blocked by 5% normal serum derived from host species of secondary 
antibodies for 1h. The slides and coverslips were subsequently incubated with 
the respective primary antibodies at the proper dilution overnight at room 
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temperature and 1h at 37°C, respectively. Details of the various primary 
antibodies used are listed in Table 1.  
After incubation with the primary antibodies, tissue sections and cells 
were washed 3 times with 1% PBS-TX for about 15min. They were incubated 
for 1h in biotinylated or fluorescence labelled secondary antibodies. Details of 
the secondary antibodies used are shown in Table 2. For biotinylated secondary 
antibodies, the slides and coverslips were washed with PBS buffer, and 
incubated with Avidin-Biotin complex (ABC reagent, Vector Laboratories., USA) 
for 1h. Immunostaining was visualized with 3,3’-diaminobenzidine 
tetrahydrochloride (DAB) as a peroxidase substrate. The reaction product was 
intensified with 0.1% ammonium nickel sulphate. The slides were finally 
counter-stained with 1% methyl green, dehydrated in graded concentrations of 
alcohol and mounted in Permount. For fluorescent secondary antibodies, the 
slides and coverslips were washed with PBS buffer, mounted with 80% glycerol 
in PBS and finally viewed under an Olympus confocal microscope. Control 
sections were incubated as above but the primary antibodies were omitted.  
The numbers of TH and MHC II-immunopositive cells in the SNc of every 6th 
section (n=4) were counted, averaged and statistically analyzed using Student’s 
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Table 1. Primary antibodies used for immunostaining 
Antigen Host 
species 
Dilution Source  
Claudin 1 goat 1:500 Santa Cruz 
Biotechnology, 
Inc 
Claudin 5 goat 1:500 Santa Cruz 
Biotechnology, 
Inc 
GFAP rabbit 1:1000 Chemicom 
CD 11b rat 1:1000 BD 
Pharmingen 
O4 rabbit 1:1000 Chemicom 
nestin mouse 1:500 Chemicon 
C1q rat 1:100 Abcam 
TH rabbit 1:500 Chemicon 
MBLA rat 1:100 Cell Science 
MBLC rat 1:100 Cell Science 
NFL Rabbit 1:1000 Chemicon 
NFH rabbit 1:1000 Chemicon 
NKG2D rat 1:50 R&D 
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Table 2. Secondary antibodies used for immunostaining 
Rae-1γ goat 1:50 R&D 
Rae-1δ goat 1:50 R&D 
H60 goat 1:50 R&D 
MHC II mouse 1:200 Chemicon 
NF-kappaB rabbit 1:100 Santa Cruz  
Biotechnology, 
Inc 
CD34 Mouse 1:50 BD 
Pharmingen 




Dilution Source  
Mouse IgG goat 1:200 Chemicon 
Rabbit IgG goat 1:200 Chemicon 
Rat IgG goat 1:200 Chemicon 
Goat IgG horse 1:200 Santa Cruz 
Biotechnology, 
Inc 
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Double labeling 
The sections were removed from the freezer and allowed to air dry for 
at least 30 minutes to ensure tissue adherence to the slides. Sections were 
blocked with 5% goat serum/PBS plus 0.2% Triton X-100 before being 
incubated with primary antibodies. For immunofluorescence, the FITC or 
Cy3-conjugated anti-rabbit or anti-mouse secondary antibody (goat polyclonal, 
1:200; Chemicon International, Temecula, CA, USA) was used, followed by 
counterstaining with DAPI and then mounted with Vectashield mounting 
medium. The slides were examined under an Olympus confocal microscope 
(LSM 510 Zeiss, Japan). 
7. Transmission Electron Microscopy (TEM) 
7.1. Conventional TEM 
Following perfusion of animals with a fixative containing 2% PF and 
3% GA in 0.1M PB (pH 7.4), the brains were removed and immersed in the 
same fixative for 4 hours at 4ºC. They were then transferred into 0.1M PB (pH 
7.4) containing 5% sucrose, where they were kept overnight at 4ºC. The fixed 
brains were then cut with a vibratome machine into 100μm-thick sections. Under 
a dissecting microscope, the SNc was cut off and removed from the fixed mid 
brain and was further trimmed into small pieces (1-3 mm2) with a razor blade. 
The tissue slices were post-fixed in 1% osmium tetroxide (OSO4) for 2 hours at 
room temperature. After osmication, the tissue slices were briefly rinsed in 0.1M 
PB (pH 7.4) and dehydrated through an ascending series of alcohol at room 
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temperature, infiltrated through series of Araldite at different temperature and 
finally embedded in Araldite, polymerized at 60ºC for 24 hours. 
Semi-thin sections (1μm thick) were cut from the blocks with a Reichert-Jung 
ultramicrotome, stained with 1% methylene blue in deionized water and 
examined. This allowed the SNc tissue blocks to be trimmed to smaller area 
containing the dopaminergic neurons. Ultra-thin sections of pale gold coloration 
cut from these blocks were collected onto Formvar coated 100-meshed copper 
grids. The sections on grids were stained with uranyl acetate for 10 minutes 
followed by lead citrate for 8 minutes. They were viewed in a Philips EM208 or 
a JEOL 1200EX electron microscope. 
7.2. Immunoelectron Microscopy 
After perfusion with a fixative containing 4% PF and 0.1% GA in 
0.1M PB (pH 7.4), the brains were removed and post-fixed for 4 hours in the 
same fixative. They were then kept in 0.1M PB (pH 7.4) containing 5% sucrose 
overnight at 4ºC. The brains were cut with a vibratome into 100μm-thick 
sections. The immuno-DAB staining followed the procedure of light microscopy 
except that Triton X-100 was omitted from the incubation medium and rinsing 
solutions. After staining, tissue sections were examined under a light microscope 
and then sub-dissected into small pieces (1-3mm2) containing identified 
immuno-labeled cells. Small tissue pieces were post-fixed in 1% osmium 
tetroxide for 2 hour at room temperature. After osmication, the tissue slices were 
briefly rinsed in deionised water and dehydrated in an ascending series of 
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ethanol and embedded in an Araldite mixture. 
Semi-thin sections (1μm thick) were cut from the blocks with an 
ultra-microtome, stained with 1% methylene blue and examined. This allowed 
the tissue blocks to be trimmed to a smaller size that includes immuno-labeled 
cells. Ultra-thin sections of pale gold coloration were collected onto 100-meshed 
copper grids coated with Formvar. The sections were stained with lead citrate 
only for 8 minutes, and viewed under a Philips EM208 electron microscope. 
8. Reverse transcriptase polymerase chain reaction (RT-PCR) 
8.1. RNA isolation 
Materials 




At each time point, the mice SNc (n=4 for MPTP-treated mice and for 
control group) were rapidly removed and frozen in liquid nitrogen. Total RNA 
was isolated from 30mg of MPTP-treated mice and 2×106 MSCs (n=4) using the 
RNeasy Mini kit according to the manufacturer’s protocol as described below. 
Tissues and cells were homogenized by a homogenizer (Ultra-turrax 
T25 basic) in 600μl of Buffer RLT (provided with the kit, containing a highly 
denaturing guanidinium isothiocyanate which immediately inactivates RNase). 
The lysate was centrifuged for 3min at 14,000g in a microfuge and the 
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supernatant containing the RNA was transferred to another 2ml plastic 
Eppendorf tube (Eppendorf Biophotometer, USA). 600μl of 70% ethanol were 
then added to the cleared lysate and mixed well to provide appropriate binding 
conditions. The sample was applied to an RNeasy mini spin column (silica-gel 
membrane, maximum binding capacity is 100μg of RNA longer than 200 bases), 
spun for 15s at 10,000g and the flow through was discarded. During this step, 
the total RNA binds to the membrane. The RNA bound to the membrane was 
washed with buffer RW1 and RPE (provided with the kit) sequentially. 
High-quality RNA was then eluted in 30μl of RNase free water. The 
concentration and purity of the extracted RNA were evaluated by 
spectrophotometric absorbance readings at 260nm and 280nm (Eppendorf 
Biophotometer, USA). 
8.2. One step RT-PCR 
Materials 
One Step RT-PCR Kit (QIAGEN, Germany); PCR machine (PCR 
Express, UK) 
Specific primers of target genes (Table 3). 
Procedure 
Reverse transcription and PCR were carried out sequentially in the 
same tube using One Step RT-PCR kit. The RT-PCR was carried out in a total 
volume of 25μl. The RNA template, primer solutions, dNTP Mix, 5× QIAGEN 
One Step RT-PCR Buffer and RNase-free water were thawed and placed on ice. 
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The master mix containing 5μl of 5× QIAGEN OneStep RT-PCR Buffer, 1μl of 
dNTP Mix, and 1μl of Enzyme Mix was prepared, mixed and allocated equally 
to PCR tubes. About 80ng of total RNA and 1μl of each primer pair was added 
into the individual PCR tubes. RNase-free water was added to make a final 
volume of 25μl. Genes were amplified in a PCR machine under the 
amplification conditions listed in Table 7. Two to three independent RT-PCRs 
were performed to control for variations between experiments. For 
semi-quantative analysis, mRNA of the housekeeping gene GAPDH was 
co-amplified under the same conditions. A no-template control in which water 
was added instead of RNA and a no-reverse transcriptase control in which water 
was added instead of the enzyme were included for each PCR batch. To control 
for potential genomic DNA contamination, the RNA templates were digested 
with RNase followed by one step RT-PCR amplification. 
Detection of PCR products 
Materials 
1.5% Agarose gel: 
Agarose (Bio-Rad) 1.5g 
Ethidium Bromide solution (Bio-Rad) 10μl 
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Procedure 
PCR products were run on agarose gel using electrophoresis. 1.5% 
agarose gel was prepared by heating agarose in the TAE buffer (0.04M Tris-base, 
0.001M EDTA, Glacial acetic acid, pH7.8). Ethidium bromide was added into 
the gel. The gel was cooled and poured onto a gel tray and allowed to solidify. 
10μl of each RT-PCR product was loaded in each lane of the gel and 
electrophoresed at 110V for 20-30min in TAE buffer along with 650ng of 100bp 
DNA ladder (Promega). 
Analysis of RT-PCR bands 
The PCR bands were visualized with an ultraviolet trans-illuminator 
and photographed (Polaroid). The 100bp DNA ladder was used to determine the 
size of the amplified DNA from 100-1500bp. 
All photographed PCR products were scanned and analyzed using 
NIH Image software. For respective samples, the PCR product values were 
normalized to the actin PCR product value. 
8.3. Real time RT-PCR 
Real time quantitative PCR is a new approach in PCR-technology. It is 
much faster and more reliable than other semi-quantitative PCR-techniques, 
such as competitive PCR and picture-analysis after eletrophoresis. The 
SYBR-Green method uses SYBR-Green I® as a fluorescent dye which 
intercalates specifically with double-strand DNA during the extension phase of 
the PCR. For quantification of the starting amount of template DNA, the 
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threshold cycle (Ct) of each sample is calculated. Ct-value is proportional to the 
logarithm of initial template DNA concentration. 
Materials 
Oligo-dT primer (Promega, USA); dNTP (Promega, USA); RNase 
inhibitor (Promega, USA);  
M-MLVRT with 5X Reaction buffer, (Promega, USA); 
LightCyclerTM-FastStart DNA Master SYBR Green I (Roche, 
Germany);  
3mM MgCl2 (Roche, Germany); LightCyclerTM real time PCR 
machine (Roche, Germany); Primers of target genes (Table 3). 
Table 3. Primers for real time RT-PCR 
Gene Primers 
 
Product size   
(bp) 
NFL Forward:5’-atcagcaacgacctcaagtctat-3’  
Reverse: 5’-tactatacctgcatggcgctaat-3’ 
800 
MBLA Forward: 5'-CAG GGT CAC AAA 
CCT GTG AG-3'   
Reverse: 5'-TGC AAC TTG TTG GTT 
AGC TG-3' 
295 
MBLC Forward: 5'-GAC CTT AAC CGA AGG TGT TCA-3'   
Reverse: 5'-CAG TTT CTC AGG 
GCT CTC AG-3' 
305 
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Procedure 
Synthesis of cDNA 
The reaction mixture containing 2μg of total RNA, 1μl oligo-dT 
primer, 5μl of 5X Reaction buffer, 1.25μl dNTP, 0.35μl RNase inhibitor, and 1μl 
of M-MLVRT was made up to total volume of 25μl with RNase-free water and 
incubated at 42ºC for 1h. The reaction was stopped by heating for 5min at 95°C. 
 
Amplification of mRNA 
An aliquot (0.5μl) of the reverse transcription products was added in 
the reaction mixture (20μl) containing LightCyclerTM-FastStart DNA Master 
SYBR Green I, 0.5μM of each primer, and 3mM MgCl2. The forward and 
reverse primers used are listed in the Table 8. After pre-incubation at 95°C for 
10min, PCR was performed with 50 cycles of denaturation at 95°C for 15s, 
annealing at temperatures corresponding to the genes (see Table 8) and 
elongation at 72°C for PCR product size/25s. The level of specific mRNA was 
quantified, expressed as Ct, the cycle number at which the LightCycler System 
detected the upstroke of the exponential phase of PCR product accumulation, 
and normalized by the level of GAPDH or ß-actin expression in each individual 
sample (Fields and Casey, 1997). To control for potential genomic DNA 
contamination, PCRs were performed without the reverse transcription step. 
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9. Western Blot assay 
Materials 
Protease inhibitor cocktail kit (Pierce, USA, Cat. No. 78410) 
Mammalian protein extraction reagent (Pierce, USA, Cat. No. 78503) 
Protein assay kit (Bio-Rad, USA, Cat. No. 5000002) 
Primary antibodies (Table 4) 
Secondary antibodies (Table 5) 
 
10% resolving gel: 
H2O          7.9ml 
       30% acrylamide mix   6.7ml 
1.5 M Tris (pH 8.8)       5.0ml 
       10% SDS         0.2ml 
       10% ammonium persulfate     0.2ml 
       TEMED      0.008ml 
5% stacking gel: 
H2O          5.5ml 
       30% acrylamide mix   1.3ml 
1.0 M Tris (pH 6.8)      1.0ml 
       10% SDS         0.08ml 
       10% ammonium persulfate     0.08ml 
       TEMED      0.008ml 
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1 SDS gel-loading buffer: 
50mM Tris.Cl (pH 6.8) 
       100mM dithiothreitol (DTT) 
       2% SDS 
       0.1% bromophenol blue 
       10% glycerol 
Tris-glycine electrophoresis buffer: 
25mM Tris 
       250mM glycine 
       0.1% SDS 
Transfer buffer: 
25mM Tris 
       250mM glycine 
       20% Methanol 
1 TBS: 
       Tris base   2.42 g 
       NaCl    0.8 g 
  H2O up to 1 liter; adjusted to pH 7.6 with 2N HCl 
1 TBST: 
       1 TBS            1 liter 
       0.1% Tween 20      1ml 
Stripping buffer (Pierce, USA, Cat. No. 0021059) 
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Procedure 
Protein extracts from brain tissues subjected to various treatments for 
different periods were prepared using the protein extraction kit and protease 
inhibitor cocktail kit, and were quantified using a protein assay kit. Briefly, the 
tissues were put in 600μl of protein extraction buffer and sonicated. The 
supernatant was collected by centrifugation at 14,000 g at 4ºC for 15 min and 
stored at -20ºC for further use.   
The concentration of protein extracts was determined using a protein 
assay kit. Four different concentrations (0.06, 0.12, 0.24, and 0.48mg/ml) of 
BSA were prepared as protein standards. 10µl of each standard or sample and 
200µl of dye reagent were added together to each well of a 96-well plate, and 
mixed thoroughly. The mixtures were incubated at room temperature for 10 
min, and the absorbance at 595nm was measured using a microplate reader 
(GENios, Tecan, Switzerland). The concentration of protein extract of the 
samples was determined according to the standard curve of BSA. 
Aliquots of protein extracts (20 µg each) were heated to 100ºC for 3 
min in 1x SDS gel-loading buffer to denature the proteins before the proteins 
were separated by 10% sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE). Next, the proteins were transferred from the gel 
to the 0.2µm PVDF membranes using a semi-dry electrophoretic transfer cell 
(Bio-Rad, USA). Membranes were washed with TBST buffer and then blocked 
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with 5% non-fat milk in TBST for 1h at room temperature. Subsequently, the 
membranes were incubated with appropriate primary antibodies overnight at 
4ºC in a shaker. Details of the various primary antibodies used are listed in 
Table 4. The next day, blots were incubated with secondary IgG antibody 
conjugated with horseradish peroxidase for 1h at room temperature. Details of 
the various secondary antibodies used are listed in Table 5. Equal amount of 
protein loading was confirmed by reprobing with total kinases or actin 
antibodies. Immunopositive bands were visualized by enhanced 
chemiluminescence (ECL), and quantified by scanning densitometer and 









Table 4. Primary antibodies used for Western blot analysis 
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Table 5. Secondary antibodies used for Western blot analysis 
Antigen Host 
species 
Dilution Source  
Claudin 1 goat 1:500 Santa Cruz 
Biotechnology, 
Inc 
Claudin 5 goat 1:500 Santa Cruz 
Biotechnology, 
Inc 
Occludin rabbit 1:1000 Invitrogen 
TH rabbit 1:2000 Chemicon 
MBLA rat 1:500 Cell 
Science 
MBLC rat 1:500 Cell 
Science 
NFL rabbit 1:5000 Chemicon 
NFH rabbit 1:5000 Chemicon 
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Antigen Host 
species 
Dilution Source  
Rabbit IgG    goat 1:5000 Pierce 
Mouse IgG goat 1:5000 Pierce 
Rat IgG goat 1:5000 Pierce 
Goat IgG     horse 1:5000 Santa Cruz 
Biotechnology, 
Inc 




10. Transplantation of MSCs via tail vein of the mice after 
MPTP-treatment 
Ninty-six male C57BL6/J mice weighing approximately 20g were 
used in this study. 
Before transplantation, MSCs were detached by trpsin-EDTA and 
resuspended in sterile PBS at the concentration of 2 × 105 cells/μl. Primary 
cultured MSCs were transplanted via the tail vein 24 hours after the last 
injection of MPTP. Mice were deeply anaesthetized. 1x105 CFDA SE-labeled 
MSCs were suspended in 100ul PBS before transplantation and then slowly 
injected into the tail vein in 5 minutes with a 27G needle. The needle was kept in 
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the tail vein for another 5 minutes to avoid regurgitation and then withdrawn. 
Vehicle controls were injected with the same volume (100 ul) of PBS via the tail 
vein 24 hours after the last injection of MPTP. The mice were placed back into 
cages where they were allowed to recover and then sacrificed at 3, 7, 14, and 28 
days post- MPTP-injection for different observations. 
 
11. Statistical Analysis 
The data of experiments were presented as mean ± SD. The standard 








where, x = individual observation, and n = number of observations 
Statistical analyses for various experiments performed in this study 
were carried out by Student’s t-test or one-way ANOVA using the Microsoft 
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1. Behavioral changes of MPTP-treated mice 
Shortly after the first injection of MPTP, mice showed hyperactivity, 
hunched posture, splayed hind limbs, erect (Straub) tail reaction and tremor 
(Fig. 5). The signs remained till next injection. After the last injection (the 
fourth), the toes of the hind feet were widely separated. However, 24h after the 









Fig.5. Behavioral changes of MPTP-treated mice. After 
MPTP-treatment, the mice exhibited hunched posture, splayed hind 
limbs and erect (Straub) tail reaction. 
 
2. Pathological observations in the MPTP-treated mouse model 
2.1. Morphological studies of dopaminergic neurons in the SNc 
To investigate the pathogenesis of PD, a MPTP-treated mouse model 
was established. The morphology of dopaminergic neurons in the SNc was 
examined by Nissl staining, immunohistological staining with anti-TH and 
electron microscopy (EM).  
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2.1.1. Nissl staining 
Nissl staining labels the Nissl bodies in the cytoplasm of the 
perikarya. Most of the neurons in the SNc became shrunken and showed 
intensive staining in the whole cytoplasm 3 days after MPTP-treatment. Some 
of the nuclei in these neurons were not even visible, indicating the shrinking of 
the nuclei (Fig. 6C). 
At 7 days after MPTP-treatment, a few small, darkly-stained, and 
shrunken neurons were still detectable (Fig. 6D). Moreover, many neurons 
appeared to be lost in the SNc at 7 days after MPTP-treatment. 
However, no such morphological changes and cell loss of the 
dopaminergic neurons were observed in the ventral tegmental area (VTA) at 
different time point post-MPTP treatment (Fig. 6B). Fig. 6A showed normal 









Fig.6. Nissl staining in the SNc and VTA. Evenly distributed Nissl 
bodies in the neurons of SNc (A) and VTA (B) became shrunken 
and intensive in the whole cytoplasm 3 days (C) and 7 days (D) 
after MPTP-treatment.  
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2.1.2. TH staining 
Tyrosine hydroxylase (TH) is the rate-limiting enzyme for the 
production of dopamine or norepinephrine. Figure 7A-D shows the 
morphological changes of dopaminerigic neurons after MPTP-treatment. 
Immunohistochemistry with anti-TH antibody revealed the shrunken cell body 
and reduced neural fibers in the positive-stained cells in MPTP-treated mice 
(Fig. 7B) compared to the saline-treated controls (Fig. 7A). 







Fig.7. Dopaminergic neuronal loss in the SNc after MPTP-treatment. Tyrosine 
hydroxylase (TH) positive dopaminergic neurons in the SNc of MPTP-treated 
mice lost (B) compared to the normal controls (A).  
 
 
Immunoreactivity for TH has been used to quantify 
catecholaminergic neurons. To confirm the rate of lost in TH staining of 
dopaminergic neurons after MPTP-treatment, the TH-positive neurons in the 
SNc sections were quantified using an optical fractionator, an unbiased 
stereological technique (Chan et al., 1997), averaged and analyzed using 
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ANOVA. The cell number counting showed that TH positive dopaminergic 
neurons in the SNc decreased significantly at 3 days post-MPTP treatment and 
even more severe afterward compared to the controls (P<0.01) (Fig. 8C). In the 
SNc of MPTP-treated mice (Fig. 8B) compared with saline-treated control 
mice (Fig. 8A), the loss of TH-positive cells were 49%, 54.5%, 55.6% and 




Fig.8. Cell number counting. Tyrosine hydroxylase (TH) positive 
dopaminergic neurons in the SNc of normal controls (A) and 
MPTP-treated mice (B). C: Numbers of TH positive cells at different 
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The results of cell counting are summarized in Table 6. To the 
contrary, cell counts of TH-positive neurons in the ventral tegmental area (VTA) 
did not reveal any significant differences between MPTP-treated and normal 
control mice (Table 7). 
 
Table 6. TH (+) cell number counting at different time points in the SNc 
(means±SEM) of normal and MPTP-treated mice (n=6).  




450±17 230±26* 205±14* 200±26* 201±11* 
*: Significantly decreased. 
 
Table 7. TH (+) cell number counting at different time in the VTA 
(means±SEM) of normal and MPTP-treated mice (n=6). 




650±21 637±39 643±20 647±23 651±17 
 
2.2. Microglial activation at SNc 
Besides the neuronal changes, immune staining with DAB also 
revealed that under high magnification of light-microscopy, CD11b positive 
microglial cells became amoeboid morphologically 3 days post-MPTP 
treatment (Fig. 9C) compared to the ramified normal controls (Fig. 9D). And 
low magnification of light-microscopy showed that the CD11b (+) cell number 
increased in the SNc of MPTP-treated mice (Fig. 9A) compared to normal 
controls (Fig. 9B).  
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Fig.9. Microglial activation in the MPTP-treated mice. staining in the 
SNc of MPTP-treated mice became ameboid (C) compared to the 
ramified normal controls (D) and the positive cell number increased in 
the SNc of MPTP-treated mice (A) compared to normal controls (B).   
 
Double-labeling of TH with major histocompatibility complex class 
II (MHC II) indicated that the activated MHC II (+) microglial cells were 
mostly located at the SNc and surrounded the TH (+) neurons in MPTP-treated 
mice (Fig. 10A) while there was no MHC II (+) staining around the TH (+) 
neurons at SNc of normal controls (Fig. 10B). This morphological change and 
activation remained until the end of the study (28 days post-MPTP treatment). 
And the cell number counting of MHC II positive staining increased in the SNc 
of MPTP-treated mice compared to normal controls (Fig. 10C), which was in 
accordance with that of CD11b positive staining. The results of cell counting 
are summarized in Table 8. 
 


















Fig.10. Microglial activation in the MPTP-treated mice. MHC II 
staining in the SNc of MPTP-treated mice became ameboid (B) 
compared to the ramified normal controls (A) and the positive cell 
number increased (C, *P<0.05).  
 
 
Table 8. MHC II (+) cell number counting at different time points post-MPTP 
treatment at the SNc (n=6). 





3±1 175±24* 165±19* 152±11* 154±20* 
*: Significantly increased. 
 
2.3. BBB integrity compromise  
The BBB is composed of microvascular endothelial cells that are 
interconnected by tight junctions, which prevent the infiltration of most 
blood-borne cells and molecules into the brain parenchyma (Prat et al., 2001). 
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Several researchers have reported the BBB compromise was involved in the 
pathogenesis of PD, however, the molecular basis are still under investigation. 
 
2.3.1. Functional study of BBB 
To investigate the integrity of the BBB, the brain microvasculature 
was visualized with intra-vascular FITC-albumin, a barrier tracer with green 
fluorescence, which was injected intravenously into both MPTP- and 
saline-treated mice 24 hours post MPTP- or saline-treatment. Brain sections 
were analyzed with a laser scanning confocal microscope. Under physiological 
conditions, albumin is restricted in the blood vessels and can not enter the brain 
parenchyma unless there is a BBB compromise. After FITC-albumin was 
injected, fluorescence leakage from the blood vessels to the cerebral 
parenchyma in the SNc of MPTP-treated mice (Fig. 11B) was observed under 
the confocal microscope compared with controls (Fig. 11A). Quantification of 
the intensive density of fluorescence at the SNc showed that the leakage was 
statistically significant (Fig. 11C). These data suggest that MPTP treatment can 
break down the integrity of the BBB in the mouse PD model. And the leakage 










Fig.11. Intravenously injected albumin-FITC was restricted in the blood 
vessels in the SNc of normal controls (A) while leaked out into the brain 
parenchyma in the MPTP-treated mice (B). Quantification of the 
intensive density of fluorescence in the SNc shows that the leakage is 
statistically significant (C, *P<0.05).  
 
2.3.2. Molecular analysis of BBB tight junction 
To investigate the underlying molecular mechanisms responsible for 
the BBB compromise, the expressions of tight junction molecules such as 
claudin 1, claudin 5 and occludin at the SNc were analyzed with 
immuno-electron microscopy (immuno-EM), confocal microscopy and Western 
blot. As shown in the left panel of figure 12, at the tight junction of SNc 
(arrow), both claudin 1 (Fig. 12A) and claudin 5 (Fig. 12C) staining under 
immuno-EM were positive in the normal control mice; while in the right panel 
after MPTP treatment, both claudin 1 (Fig. 12B) and claudin 5 (Fig. 12D) 
staining were decreased at the tight junction at the SNc (arrow).  









Fig.12. Molecular analysis of BBB in the SNc. After MPTP treatment, 
both claudin 1 (B) and claudin 5 (D) staining were decreased at the 
tight junction of SNc (arrow) compared to the normal controls (A and C, 
respectively).  
 
In addition, the EM results revealed intracellular vacuoles (arrow) in 
the perivascular cells of MPTP-treated mice (Fig. 13B) compared to control 








Fig.13. Ultrastructure of vessels in the SNc. Intracellular vacuoles 
(asterisks) in the perivascular cells were observed in the SNc of 
MPTP-treated mice (B) compared to the control (A).  
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Western blot analysis (Fig. 14A, B) showed that the expressions of 
claudin 1, claudin 5, as well as occludin were decreased at the SNc 3 days after 
MPTP treatment. The decrease of claudin 1 and claudin 5 expressions 
continued till the end of the current experiment (28 days post-MPTP treatment) 
while the decrease of occludin expression ceased at 14 days post-MPTP 
treatment and was restored at 28 days post-MPTP treatment without any other 
treatment (Fig. 14A). Semi-quantative analysis showed that statistically the 










        
Fig.14. Western blot analysis shows the expressions of claudin 1, 
claudin 5 and occludin in the SNc were decreased at 3, 7, 14 and 28 
days post-MPTP treatment (A) and the decrease is statistically 
significant (B) (*P<0.05).   
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  2.4. Peripheral inflammatory factors penetration  
2.4.1. Complement system 
The complement system belongs to the innate immune system and it 
consists of a number of small proteins which are synthesized mainly in the liver 
and found in the blood, normally circulating as inactive zymogens. To 
investigate whether complement factors such as mannose binding lectin acute 
(MBLA) and chronic (MBLC) could penetrate the compromised BBB and get 
involved in the pathogenesis of PD, the author used RT-PCR, 
immunohistochemical and immunofluoroscent staining to detect the 
expressions of MBLA and MBLC at the SNc. The right panel of figure 11 
showed increased MBLA (Fig. 15B) and MBLC (Fig. 15D) staining in the SNc 









Fig. 15. Immune staining of MBL in the SNc. Both MBLA (B) and 
MBLC (D) positive staining increased in the SNc of MPTP-treated mice 
compared to normal controls (A and C, respectively).  
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Double labelings of TH with MBLA and MBLC were carried out 
respectively. Although most positive cells were located at the SNc, only a small 
part of MBLA (Fig. 16D-F) and MBLC (Fig. 17D-F) positive staining was 
co-localized with TH positive staining but there was no MBLA (Fig. 16A-C) or 
















Fig.16. Double-labeling of MBLA with TH. The nuclei were 
counterstained with DAPI (blue). There was no MBLA (Red) positive 
staining in the SNc of normal controls (A-C) while the staining 
increased in the SNc of MPTP treated mice (D-F). The double-labeling 















Fig.17. Double-labeling of MBLC with TH. The nuclei were 
counterstained with DAPI (blue). There was no MBLA (Red) positive 
staining in the SNc of normal controls (A-C) while the staining 
increased in the SNc of MPTP treated mice (D-F). The double-labeling 
shows no co-localization between MBLC (Red) and TH (Green, D-F).  
 
To identify the types of other cells co-localized with the positive 
staining of MBLA and MBLC, double labeling with MHC II or GFAP was 
carried out respectively. Both MBLA (Fig. 18A-C) and MBLC (Fig. 19A-C) 
were found to be co-localized with MHC II, while there was no co-localization 
with GFAP (Fig. 18D-F; Fig. 19D-F), which confirmed that both MBLA and 
MBLC positive stainings were co-localized with the activated microglia, but 
not astrocytes.  















Fig.18. Double-labeling of MBLA with MHC II or GFAP. The nuclei 
were counterstained with DAPI (blue). The double-labeling shows 
MBLA (Red) was co-localized with MHC II (Green, A-C) but not GFAP 
























Fig.19. Double-labeling of MBLC with MHC II or GFAP. The nuclei 
were counterstained with DAPI (blue). The double-labeling shows 
MBLC (Red) was co-localized with MHC II (Green, A-C) but not GFAP 
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To ascertain whether the MBLA and MBLC positive stainings at SNc 
of MPTP-treated mice in the present study were expressed by local cells of the 
brain parenchyma or originated from the circulating blood, reverse 
transcription (RT) PCR using the SNc tissue was carried out. No MBLA and 
MBLC mRNA expression was found at the SNc of either MPTP-treated mice 
or the normal controls (data not shown). On the other hand, RT-PCR and 
Western blot analyses revealed that the MBLA and MBLC expressions in the 
liver increased immediately and lasted until the end of the experiment (28 days 
post-MPTP treatment) (Fig. 20). Statistical analysis showed that the increase is 
significant and the protein levels peaked at 3 days post-MPTP treatment (Fig. 
21), which was consistent with the microglial activation described above. 
These results suggest that the increased MBLA and MBLC expressions were 
originally produced in liver tissue instead of brain tissue. The MBLA and 
MBLC proteins co-localized with the microglia at the SNc were most probably 
derived from the peripheral inflammatory system through the damaged BBB 
















Fig.20. MBLA and MBLC expressions in the live tissue. The protein 
expressions of MBLA and MBLC in the liver tissue increased at different 









Fig.21. The increasesof MBLA and MBLC expressions in the liver tissue 
after MPTP-treatmentwere statistically significant (*P<0.05). 
 
2.4.2 Natural Killer (NK) cells are involved in MPTP induced Parkinson’s 
disease models through the interaction of NKG2D receptor and Rae-1γ 
ligand  
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     Figure 22 shows that there was no NKG2D expressed in normal controls 
(Fig. 22A) while in the MPTP-treated mice, NK cells were activated and the 
immunostaining of NKG2D was positive at the SNc around dopaminergic 
neurons (Fig. 22B).  
 
 







         
Fig.22. NK cells migrated to the SNc of MPTP-treated mice and were 
activated there via NKG2D (A) while no NKG2D positive staining in 
normal controls (B). EM revealed NKG2D positive (C, white arrow) NK 
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The retinoic acid early inducible proteins-1 (Rae-1) γ and δ proteins 
together with H60 protein have been reported to be the ligands of NKG2D 
expressed on the cell surface of mouse species. To investigate which ligand 
may be involved in the NK cell activation, double-labelling of Rae1γ, δ and 
H60 with TH were carried out respectively. Rae1γ was found to be expressed at 











Fig.23. Co-localization of TH with NKG2D ligands. TH was 
co-localized with Rae1γ while not Rae1δ or H60.  
 
3. Transplantation of MSCs in treatment of PD 
3.1. Genetic background of stem cells in stem cell transplantation 
Stem cells like MSCs, possessing self-renewal and multipotent 
differentiation potential, could be developed to replace or rescue the 
degenerated neurons in the CNS, given the capacity of the CNS for self repair 
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(Prockop et al., 2000). However, genetic background of stem cells should be 
take consideration seriously as genetic mutation may be one of the most 
important etiology of PD. In this study, the author has employed the 
neurodegenerative mouse lacking of NFL to isolate adult NFL-/- MSCs and 
demonstrated their ability in neural transdifferentiation from another point of 
view. 
3.1.1. Characterization of in vitro cultured MSCs 
Immunohistochemistry analysis (Fig. 24A-D) demonstrated that the 
purified MSCs were positive for CD44 (Fig. 24B), a cell surface marker for 
MSCs, while negative for CD34 (Fig. 24C), a cell-surface marker associated 






Fig. 24. Characterization of cultured MSCs. Immunofluorescence shows 
the in vitro cultured MSCs were positive for CD44 (B) staining whle 
negative for a hematopoietic marker CD34 (C). The nuclei were counter 
stained with DAPI (A); and D was the merged photo of A, B, and C.  
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3.1.2. Effect of NFL knockout on the proliferation of MSCs 
To investigate the effect of neurofilament light chain (NFL) gene 
deletion on the proliferation and differentiation of MSCs, MSCs were isolated 
from NFL knockout (NFL-/-) mice and cultured the same way as normal 
controls. Although plating cell numbers were the same (1x105/75cm plate), 
NFL-/- MSCs grew in culture dishes at a lower density in comparison with 
normal MSCs when viewed at daily check-up (data not shown). Trypan blue 
staining showed that no obvious cell death has occurred in the culture medium 
of both types of MSCs till at least 7 days of culture (data not shown). However, 
the MTS assay has shown that the proliferation of NFL-/- MSCs measured by 
viable cells was significantly lower than that of normal MSCs at different time 






Fig.25. Lower proliferation rate of NFL-/- MSCs. Since NFL-/- and 
normal MSCs were cultured in the same condition and no obvious cell 
death observed in various time intervals, significant decreases in OD 
value of formazan product in MTS assay in NFL-/- MSCs in comparison 
with that in normal MSCs at different time point have indicated less 
number of viable NFL-/- MSCs in the culture (*p < 0.01).  
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3.1.3. Effect of NFL knockout on the neuronal differentiation of MSCs 
In vitro multiple-lineage differentiation of adult MSCs from normal 
mice was confirmed based on established protocols (Ji et al., 2004; Lu et al., 
2006). In the present study, after the RA treatment, MSCs of both normal and 
NFL-/- genotypes have differentiated into nestin(+) neural precursor cells (Fig. 
22A), MAP-2(+) (Fig. 22B) or NeuN(+) neuron-like cells (Fig. 26C), GFAP(+) 






Fig. 26. Neuronal differentiation of MSCs in vitro. After RA 
treatment, NFH-/- MSCs can be induced to differentiate into cells 
expressing Nestin (A, marker for neural precursor cells, red), MAP-2 
(B, for neurons, green), NeuN (C, for neurons, red), O4 (D, for 
oligodendrocytes, green) or GFAP (E, for astrocytes, red). In MAP-2, 
NeuN, GFAP and O4 staining, the nuclei are counterstained with 
DAPI (blue). A NeuN-positive cell with its nucleus stained in red (C) 
is observed to locate closely with a NeuN-negative cell.  
 
 
RT-PCR results have confirmed that the RA treatment could induce 
expressions of NFH mRNA in both MSCs and NFL mRNA in normal but not 
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NFL-/- MSCs (Fig. 27). Interestingly, an abnormal band (about 400 bp larger 
than normal NFL gene) was detected in NFL-/- MSCs after the RA treatment.  
 
 
Fig. 27. NFL gene expression. The primers were designed to cover 
neomycin gene (1100 bp), the selective marker for NFL knockout by 
replacement of the depleted NFL sequence (700 bp). The introduction of 
the neomycin gene into the NFL depletion sequence has resulted in an 
increase in size of gene expressed from 840 bp in normal MSCs to 
1240 bp in NFL-/- MSCs after RA treatment, suggesting that the quality 
of differentiated neuron-like cells might have been altered even though 
NFL-/- MSCs still possess the ability to differentiate into neuron-like 
cells.  
In concert with mRNA expressions, the Western blot showed an 
absence in NFL protein expression in differentiated NFL-/- MSCs (Fig. 28A). 
Although NFH expression can be detected in both MSCs, a significant 
reduction in amount of NFH protein was observed in differentiated NFL-/- 





Fig.28. Western blot analysis of NFL and NFH expressions. After RA 
treatment, NFL expression (A) is totally absent in NFL-/- MSCs. NFH 
expression (A) can be observed in both NFL-/- and normal MSCs, 
however, the amount of NFH (B) is significantly reduced (p < 0.05) in 
the NFL-/- MSCs.  
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The number of NFH positive neuron-like cells increased from 
9.92 ± 1.41 per 1000 cells (without induction) to 33.39 ± 3.30 per 1000 cells 
(after induction) in the normal MSCs but the increase was from 6.79 ± 0.59 to 
12.73 ± 1.94 per 1000 cells in NFL-/- MSCs. Less neuron-like cells were 
differentiated from NFL-/- MSCs after induction in comparison to the normal 
MSCs (p < 0.01). And NFH positive dense protein accumulations was found in 
the cytoplasm of differentiated NFL−/− MSCs (Fig. 29A) and the number of 
neuron-like cells with protein aggregation increased to 8.04 ± 2.32 per 1000 
cells at 10 days after induction, in comparison to 1.61 ± 1.62 per 1000 cells 
without induction (p < 0.01). No such dense NFH accumulation was found in 
the cytoplasm of normal MSCs with or without the RA treatment (Fig. 29B). 
Morphologically, the perikaryal protein accumulations greatly resembled the 
protein aggregations in the cytoplasm of motoneurons in the spinal cord of 




Fig. 29. NFL-/- MSCs neuronal differentiation. After RA treatment, both 
NFL-/- and normal MSCs could be induced to transdifferentiate into 
NFH positive neuron-like cells. However, in NFL-/- MSCs derived 
neuron-like cells, perikaryal NFH positive accumulation is observed in 
immunohistological staining (A, arrow), compared with the normal 
control (B). The protein aggregations can also be observed in the 
cytoplasm of motoneurons in the spinal cord of NFL-/- mice (C, arrow), 
which serve as positive control.  
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3.2. Therapeutic effect of MSCs transplantation in PD 
Functional recovery of PD after intra striatum MSCs transplantation has 
been reported (Li et al., 2001) while the effect of systemic administration of 
MSCs in PD has not been reported. Here the author transplanted MSCs via the 
tail vein to investigate the effects of systemic administration of MSCs on the 
MPTP-treated mice models. For transplantation studies, in vitro clonies of 
MSCs (Fig. 30A) were pre-labeled by CFDA-SE with green fluorescence (Fig. 






Fig.30. MSCs expanded in vitro (A) and labelled with CFDA SE (B 
before transplantation).  
 
3.2.1. Systemic MSC transplantation rescues the dopaminergic neurons 
from MPTP toxicity 
Immunofluorescence showed that there was less TH staining in the 
SNc of MPTP-treated mice (Fig. 31B) compared to the controls (Fig. 31A); 
while MSCs transplantation prevented the loss of TH staining (Fig. 31C). 
TH-positive cell number counting (Fig. 31D) showed that 3 days after MSC 
transplantation in MPTP-treated mouse, the number of TH positive neurons in 
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the SNc dropped compared with that of the group which was treated only with 
MPTP. However, the number of surviving TH positive neurons increased 
significantly at 7, 14 and 28 days after MPTP treatment in the MSC 
transplantation group compared with those without MSC transplantation 













Fig.31. Dopaminergic neuron rescue. TH staining of dopaminergic 
neurons in the SNc of normal controls (A), MPTP-treated mice (B) and 
MPTP-treated plus MSCs transplanted mice (C); D: TH positive cell 
number counting in different treatment groups at different time points 
post-MPTP injection shows the difference is statistically significant 
(*P<0.01). 
 
Table 9. TH (+) cell number counting at different time points in the SNc of 
normal, MPTP-treated and MPTP+MSCs treated mice (means±SEM, n=4). 
Groups Control 3 days 7 days 14 days 28 days 
MPTP 450±17 230±26* 205±14* 200±26* 201±11* 
MPTP+MSCs 450±17 139±12 269±8** 254±16** 272±11** 
*: Significantly decreased; **: Significantly increased.  
 
3.2.2. Destination of systemically administered MSCs  
To observe the fate of transplanted MSCs, double-labelling of CFDA 
SE pre-labelled MSCs (Fig. 32B) with TH (Fig. 32C), MHC II (Fig. 32E) or 
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GFAP (Fig. 32F) were carried out respectively. MSCs were found to migrate to 
the SNc after transplantation but no co-localization of CFDA SE with MHC II 
(Fig. 32E) was observed, which suggests that the transplanted MSCs were not 
engulfed by the activated microglia. Furthermore, no co-localization of CFDA 
SE with TH (Fig. 32D) or GFAP (Fig. 32F) was observed, which suggests that 
the transplanted MSCs do not differentiate into dopaminergic neurons or 
astrocytes. Hereby the increased TH+ neurons in the MSC transplanted mice in 
current project were not differentiated from the transplanted MSCs but possibly 
derived from the host. There should be alternative explanations to account for 
the partial rescue of both morphology and number of dopaminergic neurons in 








Fig.32. Destiny of MSCs in the SNc after transplantation. 
Double-labeling of CFDA SE-pre-labeled MSCs (green, B) with TH (red, 
C), MHC II (red, E) or GFAP (red, F) shows that no co-localization of 
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3.2.3. Suppression of microglial activation 
Since MSCs has been reported to have immune modulatory effects 
on peripheral inflammation, its role in the CNS inflammation, such as 
microglial activation, was studied in this project. Immune staining with DAB 
revealed that under high magnification of light-microscopy, most CD11b 
positive microglial cells became ramified morphologically after MSC 
transplantation (Fig. 33C) compared to the amoeboid ones in the mice treated 





Fig.33. Positive staining of CD11b (B) was amoeboid in the SNc of 
MPTP-treated mice compared to the ramified normal controls (A); after 
MSCs transplantation, the CD11b staining decreased and became 
ramified (C).  
 
Double-labeling of TH with MHC II indicated that the activated 
MHC II (+) microglial cell number increased and became amoeboid 
morphologically in the SNc of MPTP-treated mice (Fig. 34B) while there was 
less MHC II (+) staining in the SNc of MPTP+MSC-treated mice (Fig. 34C) as 
well as normal controls (Fig. 34A). Cell counting showed that the number of 
MHC II-positive microglia increased after MPTP-treatment; however MSCs 
suppressed this increase at different time points after transplantation (Fig. 34D). 
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The cell number counting of MHC II positive staining was in accordance with 
















Fig.34. Decreased expressions of MHC II in the SNc after MSC 
transplantation. Positive staining of MHC II (B) was observed in the 
SNc of MPTP-treated mice compared to the normal controls (A); after 
MSCs transplantation, the MHC II (C) staining decreased. Cell 
counting shows that the decrease in the number of MHC II positive cells 
is statistically significant (D).  
 
 
Table 10. MHC II (+) cell number counting at different time points post-MPTP 
treatment in the SNc (means±SEM, n=6). 
Groups Control 3 day 7 day 14 day 28 day 
MPTP 3±1 175±24* 165±19* 152±11* 154±20* 
MPTP+MSCs 3±1 30±4** 24±7** 16±5** 7±2** 
 *: Significantly increased; **: Significantly decreased.  
 
3.2.4. Recovery of the impaired BBB  
Since BBB compromise was observed in the MPTP-treated mice, the 
author hypothesized that systemic MSC administration may contribute to the 
BBB repair at SNc and thus protect dopaminergic neurons from further attacks.  
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Firstly, the function of BBB was studied with intra-vascular 
FITC-albumin injection into both MPTP- and MPTP+MSC-treated mice. Brain 
sections were analyzed with a laser scanning confocal microscope. After 
FITC-albumin was injected, fluorescence leakage from the vessel to the 
cerebral parenchyma in the SNc of the MPTP-treated mice (Fig. 35B) was 
observed under the confocal microscope compared with controls (Fig. 35A). 
However, MSC transplantation blocked this leakage (Fig. 35C). Quantity 
analysis of fluorescence with Image J software confirmed the leakage and 
restoration (Fig. 35D). These data appeared to suggest that MPTP treatment can 
break down the blood brain barrier integrity in the mouse PD model while 








 Fig.35. Functional recovery of BBB after MSCs transplantation. 
Intravenously injected FITC-albumin was confined within the blood vessels in 
the SNc of normal controls (A) and leaked out into the brain parenchyma of 
the MPTP-treated mice (B) while MSCs transplantation restored the BBB 
integrity and no albumin-FITC leakage was observed (C). The differences 
were statistically significant.  
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On the other hand, the underlying molecular mechanisms responsible 
for the BBB recovery, the expressions of tight junction molecules such as 
claudin 1, claudin 5 and occludin in the SNc were analyzed with Western blot 







Fig.36. Western blot analysis of claudin 1, claudin 5 and occludin 
expressions in the SNc. 
 
The expressions of claudin 1, claudin 5 and occludin were increased 
in the SNc of MPTP+MSC-treated mice compared to MPTP-treated mice. The 
increase of these expressions continued till the end of the current experiment 
(28 days post-MPTP treatment). Semi-quantitative analysis of the bands 
revealed that the expressions of claudin 1, claudin 5 and occludin were 
increased in the MSC transplanted MPTP-treated mice compared to the 
MPTP-treated only mice at 7, 14 and 28 days (p<0.05) while there was no 
significant change at 3 days (Fig. 37).  
 
 











Fig. 37. The expressions of claudin 1, claudin 5 and occludin decreased 
at 3, 7, 14 and 28 days post-MPTP treatment compared to the normal 
control. However, MSC transplantation increased the expressions of 
claudin 1, claudin 5 and occludin in MPTP treated mice compared with 
those without MSC transplantation at 7, 14 and 28 days post-MPTP 
treatment and the differences were statistically significantly (*p<0.05).  
 
3.2.5. Suppression of peripheral inflammatory factor activation and brain 
infiltration 
3.2.5.1. Suppression of complement system activation 
Since MBLA and MBLC are polymorphisms, the antibodies could 
detect multiple bands under non-reduced Western blot analysis (Fig. 38).  











Fig.38. Western blot analysis of MBLA and MBLC expressions in the 
liver tissue.  
Their expressions (the sum of different bands) in the liver tissue 
decreased in the MPTP+MSC-treated mice compared to those in the mice 









Fig. 39. The expressions of MBLA and MBLC in the liver tissue 
increased at 3, 7, 14 and 28 days post-MPTP treatment compared to 
normal controls while MSC transplantation suppressed the MBLA and 
MBLC expressions in the MPTP-treated mice compared with those 
MPTP-treated mice without MSC transplantation at the same time 
points (A); and the differences were statistically significant (*p<0.05). 
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At the same time, the positive staining of MBLA and MBLC 
disappeared at the SNc of MPTP+MSC-treated mice (Fig. 40C and Fig. 40F, 
respectively) compared to the mice treated with MPTP only (Fig. 40B and Fig. 








Fig.40. Decreased expressions of MBLA and MBLC in the SNc after 
MSC transplantation. Positive staining of MBLA (B) and MBLC（E）
were observed in the SNc of MPTP-treated mice compared to the 
normal controls (A and D, respectively); after MSCs transplantation, 
both MBLA (C) and MBLC (F) staining disappeared.  
 
3.2.5.2. Suppression of NK cell activation and recruitment at the SNc 
Immune staining showed that 3 days after MSCs transplantation, the 
expressions of NKG2D and Rae-1γ were decreased in the SNc of 
MPTP+MSC-treated mice (Fig. 41).  









Fig.41. Suppression of NK cell activation by MSC transplantation. 
Immunofluorescence revealed NKG2D (B) and Rae-1γ(E) positive 
staining increased in the SNc of MPTP-treated mice  compared to 
normal controls (A and D, respectively), while MSC transplantation 
suppressed NKG2D expression (C) and Rae-1γ expression (F).  
 
Cell number counting analysis revealed that the decrease of NKG2D 
positive cells was statistically significant. The results of cell counting are 
summarized in Table 11. 
 
Table 11. NKG2D (+) cell number counting at different time points post-MPTP 
treatment in the SNc (means±SEM, n=6). 
Groups Control 3 days 7 days 14 days 28 days 
MPTP 0±1 161±17* 159±20* 142±13* 140±25* 
MPTP+MSCs 0±1 50±11** 29±6** 21±7** 18±3** 
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4. Immune potential analysis of mesenchymal stem cells 
Previous reports suggested that MSCs exhibit allogenic escape during 
transplantation. Recent studies have reported that MSCs have an 
immunomodulatory effect on antigen presenting cells, T cells and natural killer 
cells. The current observations also showed that MSCs had immune 
suppressive effects on neuroinflammation in vivo. However, the exact 
mechanism for the immune modulatory effect is not completely understood. 
Here the expression of immune modulators such as TGF-β1 and IL-6 by MSCs 
were examined.  
4.1. Cytokine release in vitro  
In the present study, the author examined the effect of 
lipopolysaccharide (LPS) on CD44+/CD34- MSCs in vitro and the underlying 
signaling pathway. Enzyme-linked immunosorbent assay ELISA showed that 
under normal condition, MSCs expressed TGFβ1 and IL-6 in in vitro culture 
system; and when incubated with 1μg/ml LPS for 6 hours, TGFβ1 and IL-6 





Fig.42. TGF-β1 and IL-6 release in MSCs in vitro. Enzyme-linked 
immunosorbent assay (ELISA) shows increased protein levels of IL-6 
and TGF-β1 in the culture medium of MSCs 6 hrs after LPS (1μg/ml) 
treatment. 
RESULTS                                                         111 
Immunologic staining also revealed that together with the activation 
of MSCs, the immunologic transcription factor nuclear factor kappa B 
(NF-kappa B) was translocated from the cell cytoplasm (Fig. 43A) to the cell 







Fig.43. NF-КB nuclear translocation in MSCs. Immunofluroscence 
showed that 30 min following LPS (1μg/ml) treatment, there was an 
increase of NF-КB in the nucleus of MSCs (B) compared with the 
normal controls (A). Electrophoretic Mobility Shift Assays (EMSA) (C) 
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4.2. Cytokine release in vivo 
        Immunofluorescent staining showed that after transplantation, the 
CFDA SE pre-labeled MSCs migrated to the SNc and were co-localized with 













Fig.44. TGF-β1 and IL-6 release in MSCs in vivo. Double-labeling of 
TGF-β1 (A) or IL-6 (D) with CFDA SE pre-labeled MSCs (B and D, 
respectively) showed co-localization of TGF-β1 (C) and (IL-6) with MSCs 
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1. MPTP-treated mouse as a model to study Parkinson’s disease (PD) 
Dopamine neurons are compartmentalized into anatomically and 
functionally distinct groups in the mammalian central nervous system (Prakash 
and Wurst, 2006). The two largest groups are located in the midbrain: namely 
substantia nigra pars compacta (SNc) and ventral tegmental area (VTA). SNc 
neurons are functionally a component of the basal ganglia and provide 
ascending dopaminergic input to the neostriatum. They are involved in 
regulating voluntary movements and postural reflexes. VTA neurons located 
just medially to the SNc give rise to mesolimbic and mesocortical ascending 
dopaminergic fibres projecting diffusely to multiple cortical and subcortical 
structures. VTA neurons are thought to be involved in reward, attention, and 
regulation of addictive or emotional behaviors. A third population of midbrain 
dopamine neurons resides in the retrorubral field and projects primarily to the 
dorsal striatum and the pontomedullary reticular formation; it is thought to play 
a role in orofacial movements. Due to their diverse anatomy and disparate 
functions, different populations of dopamine neurons have been specifically 
implicated in a variety of neurological disorders.  
Parkinson's disease (PD), a common extrapyramidal movement 
disorder, is associated with selective neurodegeneration of SNc dopaminergic 
neurons (Hirsch et al. 1988; Kanaan et al., 2008b). VTA neurons are much less 
affected, and dopamine neurons in other regions are spared. This selective 
anatomic pattern appears to be conserved between PD patients and animal 
DISCUSSION                                                     115 
models of the disorder (Dawson et al. 2002). 
Animal models are an important aid to study pathogenic 
mechanisms and therapeutic strategies in human diseases. Since the 
pathogenesis and therapy of PD is still not well understood to date, it is of great 
importance to develop animal models for the treatment of this disease. A 
variety of experimental PD models has been established using pharmacological 
agents or environmental toxins in different species (Anderson et al., 2007; Patel 
et al., 2007; Simola et al., 2007), among which, the MPTP induced mouse is 
one of the most commonly used animals to study PD. Although several studies 
suggested that there were behavioral changes in the mice after MPTP-treatment 
(Gunzler et al., 2007; Reksidler et al., 2008), the results in the present study 
indicate that the acute MPTP-treated mouse is not a good animal model to 
study the behavior of PD. However, the response including the neuronal, glial 
and peripheral alterations to MPTP-treatment is complex and the mechanisms 
are often poorly understood (Jackson-Lewis and Smeyne, 2005; Smeyne and 
Jackson-Lewis, 2005; Watanabe, 2005; McGeer and McGeer, 2008). In order 
to have a better understanding of the mechanisms underlying the degeneration 
of dopaminergic neurons and the managements, continued investigation would 
be necessary to study the molecular signals leading to dopaminergic neuron 
loss following MPTP-treatment.  
In the present study, the acute mouse PD model was established 
according to previous report (Jackson-Lewis and Przedborski, 2007.) with a 
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regimen of MPTP (20mg/kg body weight) intraperitoneal injection 4 times with 
an interval of 2 hours. The degenerating neurons in the SNc of mice after 
MPTP-treatment were shown by Nissl staining, tyrosine hydroxylase (TH) 
staining and electron microscopy (EM).  
Immunoreactivity for TH has been used to quantify 
catecholaminergic neurons (Zecca et al., 2008). To confirm the death rate of 
dopaminergic neurons after MPTP-treatment, the TH-positive neurons in the 
SNc sections were quantified using an optical fractionator, an unbiased 
stereological technique (Chan et al., 1997), averaged and analyzed using 
ANOVA. Quantification of analysis of the number of TH+ dopaminergic 
neurons revealed a rapid neuronal loss in the SNc of adult mice at early stage 
(3 days after acute MPTP-treatment), confirming the death of certain 
dopaminergic neurons in the SNc. By 3 days post-MPTP administration, 
dopaminergic neurons at the SNc were found to be undergoing apoptosis and 
immune staining identified a 49% TH positive cell loss compared to the normal 
controls. At 7 days post-MPTP administration, more TH positive neuronal loss 
(54.5%) was found while at 14 days and 28 days post-MPTP treatment, no 
further cell death was found. This is in concert with the report that the model is 
stable at 7 days after the last injection of MPTP (Jackson-Lewis and 
Przedborski, 2007). 
Nissl staining and EM also revealed degenerating neurons in the SNc. 
Moreover, the author of the present study also observed that although there was 
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significant neuronal loss in the SNc, the quantification of TH+ dopaminergic 
neurons in the ventral tegmental area (VTA) did not reveal any significant 
change after MPTP-treatment. These results were consistent with previous 
reports demonstrating the selective loss of dopaminergic neurons in the SNc of 
PD (Fearnley and Lees, 1991; Damier et al., 1999; Maingay et al., 2006). The 
intrinsic difference due to different anatomical architecture in dopaminergic 
neurons of SNc and VTA may partially account for their different response to 
MPTP-treatment. Although further investigations are needed to establish the 
molecular basis of their different responses, this is not the scope for the present 
study. Instead, the author of the present study examined the roles of both CNS 
and peripheral immune responses which could be involved in the 
neurodegeneration to address the pathogenesis of dopaminergic neuronal death 
in the SNc after MPTP-treatment.  
2. Pathogenesis in MPTP induced PD model 
Although the initial causative factors of PD are multifactorial, they 
all lead to the nigrostriatal dopaminergic neuron death and dopamine depletion 
in the striatum. Emerging evidences suggest that oxidative stress, 
mitochondrial dysfunction, excitotoxicity, aberrant proteolitic degradation and 
inflammation may be relevant to the pathogenesis of PD (Dawson and Dawson 
2003; Smeyne and Jackson-Lewis, 2005). 
Long considered to be an immune-privileged site because of the 
presence of the blood–brain barrier (BBB) and the lack of a lymphatic system, it 
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is now well documented that the brain has full inflammatory response to 
stimulations (Engelhardt, 2006; Kuenz et al., 2008; Ji et al., 2008). 
Here, the author of the present study demonstrated that besides the 
direct toxicity on dopaminergic neurons, the MPTP induced Parkinson’s 
disease models involved the following factors: i) Activation of microglia; ii) 
BBB compromise; iii) Peripheral inflammatory factors such as complement 
system and natural killer (NK) cells. 
 
2.1. Microglial activation in the substantia nigra pars compacta (SNc) after 
MPTP treatment 
Microglial cells are resident immunocompetent and phagocytic cells 
in the CNS, and are thought to mediate the innate defence system and thus 
serve a critical role in normal CNS function (Kim and de Vellis, 2005). 
2.1.1. MPTP treatment results in activation of microglia 
In concert with previous studies (Sawada et al., 2007; Yasuda et al., 
2007), significant loss of dopaminergic neurons in the SNc accompanied with 
activation of microglia have been observed in the MPTP model in the present 
study. CD11b positive microglial cells became amoeboid 3 days after MPTP 
treatment while they appear ramified under normal conditions. The 
morphologic change was most obvious at 3 days and remained until the end of 
the present study (28 days after MPTP treatment). The morphological changes 
are consistent with other report in MPTP treated animal models (Yasuda Y, 
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2007; Kanaan et al., 2008a). Together with the morphologic changes, the 
microglial cells were positively stained with MHC II after MPTP-treatment, 
suggesting the involvement of microglial activation in the pathogenesis of PD 
(Hayes et al., 1987; Imamura et al., 2003). However, the mechanisms 
underlying the microglial activation and relationship between microglial 
activation and dopaminergic neuron loss are still not well understood (Kim and 
Joh, 2006; Whitton, 2007).  
2.1.2. Possible mechanisms involved in microglial cytotoxicity  
Inflammation is a two-edged sword. In acute conditions, it protects 
tissue against invading agents and promotes healing. On the other hands, when 
chronically sustained, it can cause serious damage to the host’s own tissue. 
While microglial activation is necessary and critical for host defense, 
overactivation of microglia is neurotoxic (Polazzi and Contestabile, 2002; 
McGeer et al., 2005). They release inflammatory cytokines that amplify the 
inflammatory response by activating and recruiting other cells to the brain 
lesion. It has been suggested that the increased pro-inflammatory cytokine 
release may be responsible for the deleterious effect of activated microglia. 
Tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interferon-γ 
(IFN-γ) (Boka et al., 1994; Hunot et al., 1999) are the main proinflammatory 
cytokines produced by microglia during CNS inflammation. Sustained 
over-activation of microglia has been observed in multiple neurodegenerative 
diseases. It has been shown that the levels of cytokines such as TNF-α, IL-1β 
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and IFN-γ are elevated by 7- to 15-fold in the SN of PD patients (Mogi et al., 
1994; Hirsch et al., 1998) and the increased expressions of these cytokines 
could enhance the susceptibility of dopaminergic neurons to degeneration 
(Koprich et al., 2008) while neutralizing of these cytokines has been shown to 
protect against dopaminergic neurotoxicity (McCoy et al. 2006). 
In the present study, CD11b and MHC II staining showed the 
activation of microglia/macrophages in the SNc after MPTP-treatment and 
hence, the activated microglia subsequently may release neurotoxic factors 
which may be involved in the degeneration of dopaminergic neurons in the 
SNc. Another deleterious effect of activated microglial cells is phagocytosis. 
MHC II was found on microglia/macrophages, dendritic cells and B cells, all of 
which are professional antigen-presenting cells (APCs). Once activated and 
bind to targeting cells, MHC II could lead to phagocytosis and digestion of 
targeting cells by microglial cells (Cho et al., 2003). 
It has, however, been suggested that even at this point the numbers of 
microglia can decrease and lose their activation markers, subsequently 
returning to the resting state if the activating stimulus disappears. However, if 
the pathologic stimulus is maintained, substantial increases in activation 
markers and cell adhesion molecules occur and finally the activated microglia 
cluster around DA neurons and become phagocytic (Bronstein et al., 1995; 
Banati et al., 1998; McGeer, 1998). This combination of released factors and 
surface adhesion to dopaminergic neurons leads to a progressive and 
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irreversible neuronal cell death, which is worsened by the release of 
chemoattractants by the dying neurons to induce even greater infiltration of the 
region by activated microglia (Aloisi, 2001; Kim and De Vellis, 2005; Sriram 
et al., 2006). 
2.1.3. Possible factors to active microglia in MPTP-PD model 
To date, no report has demonstrated that MPTP can directly activate 
microglial cells. The mechanisms initiating deleterious neuroinflammation in 
PD are still poorly understood.  
Several molecules, including LPS, IFN-γ, chemokines, 
neurotransmitters and gangliosides, and several proteases such as thrombin, 
tissue plasminogen activator (tPA) and matrix metalloproteinase- 3 (MMP-3) 
are found to be involved in microglial activation. Some of them are from 
neurons and others are from pathogens, immune cells or microglia themselves 
(Abd-el-Basset and Fedoroff, 1995; Tsirka, 1997; Suzumura et al., 1998; Tan et 
al., 1999a; Aloisi et al., 1999b; Moller et al., 2000; Kim et al., 2005). 
Several lines of evidence suggest that adult microglia can also 
become chronically activated from a single stimulus in the absence of any 
predisposed event or aging. For example, chronic microglial activation 
continues years after brief MPTP exposure in humans (Langston et al., 1999) 
and primates (McGeer et al., 2003) through a process called reactive 
microgliosis. Reactive microgliosis is defined by the microglial activation that 
occurs in response to neuronal damage. This microglial activation is then toxic 
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to neighboring neurons, which causes further microglial activation and a 
self-propelling progressive cycle of inflammation and neuron damage. 
Regardless of the class of instigating stimuli (pro-inflammatory toxin or 
neuronal death) the microglial pro-inflammatory response to neuron damage 
can drive the progressive inflammation and cumulative loss of neurons over 
time (Block and Hong, 2005).  
However, the mechanism by which neurodegeneration come to incite 
an inflammatory or autoimmune response is poorly understood. The 
identification of the stimuli and mechanisms responsible for progressive 
microglial activation and associated continuous neuronal damage is essential to 
understand the etiology and pathology of PD. The current study has indicated 
the disruption in integrity of the BBB may be a key factor in initiating 
microglial activation. 
 
2.2. BBB integrity compromise 
In the normal CNS, brain tissue provides an immunosuppressive 
environment, which seems to be important for proper function of the CNS. This 
immunosuppressive environment is supported by several molecules including 
the BBB cellular components (Cserr and Knopf, 1992; Perry, 1998; Bechmann 
et al., 1999). Under circumstances that cause the disruption of this environment, 
such as infectious diseases, autoimmune diseases or chronic inflammatory 
conditions in neurodegenerative diseases, a variety of immune regulatory and 
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inflammatory mediators can be activated and damage the BBB reciprocally 
(Zhao et al., 2007). 
The results in the present study have suggested involvement of 
peripheral immune elements in microglial activation of the CNS immunity in 
the MPTP model. The establishment and maintenance of tight junctions are 
crucial to both the development and normal functioning of most organs. 
Several proteins, such as claudin 1, claudin 5, and occludin, have been found to 
be localized at the tight junctions and served as functional markers for the tight 
junction (Matter and Balda 2003; Papadopoulos et al., 2004; Nag et al., 2007). 
In the present study, the expressions of claudin 1, claudin 5 and occludin were 
reduced at tight junctions of the blood vessels in the SNc of the MPTP-treated 
mice compared to those in the normal controls. These data suggest that MPTP 
treatment could compromise the BBB through decreasing the tight junction 
molecules such as claudin 1, claudin 5 and occludin in the mouse PD model.  
The electron microscope observation has further confirmed the loss 
of claudin 1 and claudin 5 molecules in tight junctions of capillaries. As a result, 
the permeability of the BBB increased, indicated by the leakage of 
FITC-albumin and infiltration of MBL from blood into brain parenchyma.  
Therefore, interruption of the integrity of the BBB may result in 
peripheral factors to enter the brain parenchyma that lead to the activation of 
microglia or even other immune cells to invade into the brain parenchyma and 
directly add toxic effect on neurons. 
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2.3. Penetration of peripheral inflammatory factors  
Today, we accept the view that the BBB limits the entry of plasma 
components, red blood cells, and leukocytes into the brain. Since the integrity 
of BBB was compromised after MPTP treatment in the present study, some 
peripheral inflammatory factors, such as mannose binding lectin (MBL) and 
natural killer (NK) cells may be transported to the brain parenchyma and play a 
role in the pathogenesis of PD.  
2.3.1. MBL 
C1q, mannose-binding lectin (MBL), and pulmonary surfactant 
protein A (SPA) interact with human monocytes and macrophages, resulting in 
the enhancement of phagocytosis of suboptimally opsonized targets through 
binding to the common C1q receptor (C1qR) (Tenner et al., 1995). A recent 
study has suggested that human MBL in the absence of MBL associated serine 
proteases (MASP) stimulates macrophage phagocytosis of E. coli by bridging 
targets and phagocytes (Shiratsuchi et al., 2008). As a special type of 
macrophage, microglial cells were observed to be activated in the SNc of the 
mice after MPTP-treatment in the present study. Taking together that microglial 
cells also express the MBL receptor C1qR (Korotzer et al., 1995; Wing et al., 
1999), the present author has speculated that MBL may be involved in the 
activation of microglia and thereafter enhance their phagocytosis as well as 
cytotoxicity in the pathogenesis of PD.  
In the present study, the author demonstrates that acute 
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intraperitoneal MPTP injection results in increased MBL expression in the liver 
tissue, which infiltrate into the SNc of the brain parenchyma and interact with 
microglial cells that continues for at least one month without any further 
treatment.  
MBL is synthesized in hepatocytes in the liver tissue and released 
into circulating blood. The protein does not pass through the BBB under 
physiological conditions. In the present study, the PCR results demonstrated no 
expression of MBL mRNA in the tissue of the SNc while the author observed 
MBL immuno-positive cells co-localized with microglia in the SNc. This 
suggests that local cells in the SNc would not synthesize and release MBLA 
and MBLC. The MBLA and MBLC proteins bound to microglia in the SNc are 
most probably derived from peripheral inflammatory system through the 
compromised BBB.  
MBL has been reported to bind with C1qR on the surface of 
microglia and activate microglia to release some pro-inflammatory factors, 
which may exacerbate the process of neuronal damage (Webster et al., 2001; 
Whitton, 2007). MBL has also been reported to cooperate with toll like 
receptors and amplifies the host response to pathogens (Ip et al., 2008). Based 
on the observations in the present study and other reports, the author speculates 
that binding of MBLs to microglial cells might be involved in the pathogenesis 
of PD. The exact relationship between MBL and microglial activation as well 
as dopaminergic neuron degeneration should be further studied. The MBL 
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knockout mice (Takahashi et al., 2002) will be a possible good model for future 
work. 
Hence, it is presumed that an effective control of the serum level of 
mannose binding lectin might be a novel therapeutic strategy to protect 
dopaminergic neurons in the PD model.  
However, the mechanisms responsible for the enhancement of MBL 
under MPTP-treatment are not clear. One possible reason is that after 
MPTP-treatment, some pro-inflammatory cytokines such as TNF-α and IFN-γ 
released by microglia enter the blood circulation through the compromised 
BBB and reach the liver, where they activate the hepatocytes to synthesize and 
secrete MBL (Liu et al., 2001). Another possible explanation is that MPTP 
stimulate the hepatocytes directly to synthesize MBL, but the evidence is 
absent to date. Further studies such as treating hepatocyte directly with MPTP 
in vitro and measuring the MBL expression may provide some clues. 
2.3.2. NK cells 
Another important peripheral immune factor circulating in the blood 
stream is the natural killer (NK) cell. NK cells attack apoptotic cells, but the 
receptors and ligands that stimulate them are poorly understood. The activity of 
NK cells is regulated by members of multiple receptor families such as 
natural-killer group 2, member A and D (NKG2A and NKG2D) (McQueen and 
Parham, 2002; Diefenbach and Raulet, 2003). NKG2A receptors recognize 
MHC class I molecules of human leukocyte antigen E (HLA-E) on target cells, 
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and conduct inhibitory signals (Lazetic et al., 1996; Braud et al., 1998), 
whereas NKG2D receptors recognize MHC class I-related chain (MIC), and 
conduct excitatory signals (Bauer et al., 1999; Cosman et al., 2001). Two 
murine ligands for the receptor NKG2D, H60 and retinoic acid early 
inducible-1 (Rae-1), are distant relatives of major histocompatibility complex 
class I (MHC I) molecules. Expressions of the NKG2D ligands are low or 
absent in normal adult tissues; however, they are constitutively expressed in 
some tumors and upregulated by retinoic acid. Ectopic expression of Rae-1 and 
H60 confers target susceptibility to NK cell attack. Flow cytometry analysis 
revealed that the total NK cells increased, while NKG2A expression was down 
regulated and NKG2D expression remained the same level in the blood of PD 
patients compared to non-PD patients (Mihara et al., 2008). However, the 
expression of NKG2D in the brain as well as the role of NK cells in the 
pathogenesis of PD has not been elicited. 
To investigate whether NKG2D is involved in the pathogenesis of PD, 
the receptor and its ligand were analyzed by immune staining in the 
MPTP-treated PD models in the present study. Here in the current study, 
increased NKG2D positive NK cells were observed to accumulate in the SNc 
of MPTP-treated mice. Co-localization of TH with Rae-1γ under double 
immunofluorescent staining indicates that dopaminergic neurons may express 
the ligand of NKG2D receptor, which may lead to the interaction of NK cells 
with apoptotic dopaminergic neurons. The present study is the first to identify 
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the direct evidence that the increase in number of NK cells parallel to 
dopaminergic neuron loss in the MPTP-treated mice, suggesting the possible 
involvement of NK cells in the loss of dopaminergic neurons. Immune 
modulation of the NK cell activity may have promise in the treatment of PD. 
Understanding the molecular mechanisms underlying the 
degeneration or survival of dopaminergic neurons in the SNc after 
MPTP-treatment may provide insight into the mechanisms of progressive 
neural injury in PD patients. It is hoped that this may contribute to the 
development of therapeutic strategies to interfere with neurodegeneration or to 
promote survival of the degenerating neurons. 
On the other hand, there is accumulating evidence that stem cells like 
MSCs, possessing self-renewal and multipotent differentiation potential, could 
be developed to replace or rescue the degenerating neurons in the CNS, given 
the capacity of the CNS for self repair (Prockop et al., 2000). However, for the 
purpose of cell replacement in cell therapy strategy, genetic background of 
stem cells should be taken into consideration seriously as genetic mutations 
may be one of the most important etiology of PD. The MSCs isolated from 
patients with a genetic mutation may carry on the same genetic background 
which may not be suitable for replacement of impaired cells. Thus, for 
understanding the autologous MSC transplantation for cell therapy, one of the 
important aspects of stem cell research is the influence of genetic deficiency on 
the proliferation and neuronal differentiation of MSCs, which could provide 
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clues for the destination of transplanted MSCs.  
In this part of the present study, the author first attempted to 
investigate the hypothesis that genetic mutations might alter the proliferation 
and neuronal differentiation of MSCs in vitro. Neurofilament has been reported 
to be involved in the pathology of PD (Goldman et al., 1984; Al-Chalabi and 
Miller, 2003), hence in the present study the NFL-/- mice with targeted 
disruption of neurofilament light chain were used to be the donator of NFL-/- 
MSCs.  
3. Effect of NFL knockout on the proliferation and neuronal 
differentiation of MSCs 
It would be ideal to replace diseased or injured neurons with newly 
generated neurons from self-originated stem cells in cell therapy. Although 
MSCs from the bone marrow have been confirmed to possess stem cell 
properties of self-renewal and multi-transdifferentiation, doubts are still cast on 
the ability of MSCs to differentiate into neurons. In the present study, the 
author employed the neurodegenerative mouse lacking in NFL to isolate adult 
MSCs and demonstrated their ability in neural transdifferentiation from another 
point of view. 
3.1. Characterization of in vitro cultured MSCs  
Cell transplantation in the treatment of PD has been investigated by 
many researchers. Mesenchymal stem cells (MSCs) can be isolated from 
several tissues; however bone marrow is the most often used. In the present 
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study, MSCs were isolated from the femurs and tibiae of adult C57BL6/J mice 
and propagated as colonies in vitro as reported previously (Ji et al., 2004). 
Immunohistochemistry analysis demonstrated that the MSCs used in the 
present study were CD44+/CD34-. CD44 had been reported as a cell surface 
marker for MSCs (Dvorakova et al., 2008; Dominici et al., 2006), while CD34 
is a cell-surface marker associated with hematopoietic precursor cells and 
endothelial cells but negative marker for MSCs (Kemp et al., 2005). 
 
3.2. Neuronal differentiation of NFL-/- MSCs 
Neurofilaments are important and specific molecular components of 
neurons which are normally involved in the maintenance of neuronal caliber 
(Sakaguchi et al,. 1993; Al-Chalabi and Miller, 2003). In concert with other 
reports (Ji et al., 2004; Dezawa et al., 2005a; Lu et al., 2006), the present 
results showed that MSCs from both mice could be induced by the RA 
treatment to express GFAP, O4, Nestin, MAP-2 or NeuN, suggesting that 
MSCs possess neuronal lineage differentiation potential. The present results 
further demonstrated that MSCs from normal mice could differentiate into cells 
expressing both NFH and NFL, pointing out another evidence of neuronal 
properties of differentiated MSCs. Interestingly, no NFL expression at both 
mRNA and protein levels was detected in differentiated NFL−/− cells after the 
RA treatment. However, the dense perinuclear protein accumulation indicated 
by NFH staining was observed in some differentiated NFL−/− cells and 
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morphologically the NFH-positive protein aggregation was similar to that in 
the cytoplasm of the motoneuron in the spinal cord of NFL−/− mice. The 
neurofilament aggregations in the perikarya of neurons are thought to be 
caused by the failure in normal assembly of NFL, NFM and NFH triplets after 
the targeted disruption of NFL in mice (Zhu et al., 1997). Protein accumulation 
is one of the hallmarks in neurodegenerative diseases, such as ALS (Zhu et al., 
1997), PD (Trojanowski and Lee, 1998) and AD (Wong et al., 2000). Although 
NFL gene may not be a real causative factor for PD (Rahner et al., 2002), 
down-regulation of NFL mRNA expression has been reported in some cases of 
these diseases (Bergeron et al., 1994; McLachlan et al., 1988; Wong et al., 2000; 
Menzies et al., 2002). The ability of MSCs to differentiate into protein 
aggregate-containing neuron-like cells in the present study has definitely not 
only added further token to the MSC potential in generation of neurons, but 
also provided a possible approach as a cell model to study pathogenesis of 
neurodegenerative diseases. There were about 20% less neurons in the spinal 
cord of NFL−/− mice (Zhu et al., 1997), suggesting a deficiency in neuronal 
differentiation in neuronal progenitors.  
3.3. Proliferation of NFL-/- MSCs 
In agreement with differentiation deficiency of neuronal progenitors 
in vivo, the present cell proliferation assessment has shown a significant 
decrease in proliferation of NFL-/- MSCs in vitro in comparison with that in 
normal MSCs. Significant reductions in amount of NFH protein and in the 
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number of neuron-like cells in differentiated NFL−/− MSCs compared with 
that in differentiated normal MSCs may also indicate a deficiency in neuronal 
differentiation. Although the present author does not understand the exact 
mechanism involved in this reduced proliferation and neuronal differentiation 
in both neuronal progenitors and MSCs, NFL might be somehow important for 
stem cell renewal and differentiation both in vivo and in vitro. 
In conclusion, the generation of protein-accumulating neurons in 
vitro has not only confirmed the neuron generating ability of MSCs but also 
points out a serious concern for application of stem cells in cell therapy, where 
the differentiation could inherit the feature of the original gene deficiency. The 
newly generated genetically deficient cells might not be able to fulfill the 
purpose of replacement of original diseased cells because the adult stem cells 
may possess the same genetic deficiency and that the embryonic stem cells may 
have other genetic deficiencies. It is important in cell replacement strategy to 
monitor the stem cell genetic background and to modify the genetic deficiency 
if any is present. However, diseased neuron-like cells generated from stem cells 
may serve as a cell model for studying the mechanism involved in pathogenesis 
and treatment. 
Recent studies also indicate that MSCs have an immune modulating 
effect on almost all major immune cell populations (Di Nicola et al., 2002; Le 
Blanc et al., 2003; Jiang et al., 2005; Corcione et al., 2006). Another aspect of 
the present study is to investigate the neuronal rescue and immune modulating 
DISCUSSION                                                     133 
effects of MSC transplantation in the MPTP-treated mice. 
 
4. In vitro analysis of immune potential of mesenchymal stem cells 
MSCs have gained attention because of their ease for in vitro 
expansion together with their multilineage potential. More recently, in vitro and 
in vivo immunosuppressive properties of MSCs have been described (Di Nicola 
et al., 2002; Le Blanc et al., 2003; El-Badri et al., 2004; Jiang et al., 2005; 
Corcione et al., 2006; Uccelli et al., 2006), as they are able to modulate the 
function of antigen presenting cells, T cells and natural killer cells, thus 
suppress immune responses. The underlying mechanisms of their immune 
modulation are not completely understood, but still they represent important 
candidates for manipulation of the immune response in graft versus host 
disease and autoimmune disorders. 
Several studies indicate that MSCs express toll-like receptors (TLR) 
which could bind to endotoxin, also named lipopolysaccharide (LPS). To 
investigate the responses of MSCs to inflammatory environment, LPS was used 
to treat the CD44+/CD34- MSCs in vitro in the present study. Cytokine release 
and the underlying signaling pathway were examined. Enzyme-linked 
immunosorbent assay (ELISA) show that under normal condition, almost all 
MSCs express TGF-β1 and IL-6 in in vitro culture system; and when incubated 
with 1μg/ml LPS for 6 hours, the releasing of the above cytokines in the culture 
medium increased significantly (p<0.05). Immunologic staining showed that 
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together with the activation of MSCs, the immunologic transcription factor 
nuclear factor kappa B (NF-kappa B) was translocated from the cell cytoplasm 
to the nucleus, and electromobility gel shift assay (EMSA) also confirmed this 
nuclear translocation. When MSCs were pre-treated with BAY 11-7082 (the 
NF-kappa B inhibitor), the expressions of the above cytokines decreased 
dramatically. The present results suggest that MSCs could express cytokines 
which may have immune modulating effect mediated through the NFkappaB 
pathway. MSCs may be involved in immune response after transplantation. 
However, the effect may be balanced by the pro- and anti-inflammatory factors. 
 
5. Systemic MSC transplantation rescue the dopaminergic neurons from 
MPTP toxicity 
Cell transplantation in the treatment of PD has been investigated by 
many researchers. MSCs can be isolated from several tissues but bone marrow 
is most often used. Although some reports suggested that MSCs could 
differentiate into neuron-like cells under certain conditions and can be used for 
cell replacement (Wislet-Gendebien et al., 2005; Tropel et al., 2006; Trzaska et 
al., 2007), there are still controversial issues (Bertani et al., 2005; Chen et al., 
2006; Choi et al., 2006). At the least, MSCs with genetic mutation may not be a 
good cell resource for replacement of lost neurons. 
However, we may be able to take advantage of bio-factors released 
from MSCs in the future treatment of PD. The present results also suggest 
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MSCs are immune modulators both on peripheral and central nervous system 
inflammation in the MPTP-treated mice, which provide an alternative 
explanation for the possible beneficial effects of MSCs transplantation in PD. 
5.1. Rescue of dopaminergic neurons by MSC transplantation 
In order to identify the potential effect of MSC transplantation in PD 
and the underlying mechanisms, pre-labelled MSCs were injected into 
MPTP-treated mice through the tail vein. The systemically transplanted MSCs 
were found to migrate to the SNc after transplantation, which was in 
accordance with the report that the stem cells circulating in the blood could 
cross the BBB under certain conditions (Tan et al., 2005). However, no 
co-localization of TH with pre-labelled MSCs was observed at different time 
points post-transplantation (3, 7, 14, and 28 days), which is inconsistent with 
other reports that MSCs could be induced to express dopaminergic neuronal 
marker TH under favourable conditions and can replace damaged dopaminergic 
neurons after transplantation (Dezawa et al., 2005b, 2005c; Tropel et al., 2006).         
The present results have demonstrated that MSCs transplanted via the 
tail vein after MPTP treatment in mice have significantly preserved the number 
of TH positive dopaminergic neurons in the SNc. The preserved dopaminergic 
neurons may have either differentiated from the transplanted MSCs or from the 
dying host neurons rescued by MSC transplantation. However, 
non-colocalization of TH with pre-labeled MSCs suggests that the increase in 
number of dopaminergic neurons in the SNc was not coming from 
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differentiated MSCs. Although this may partially be due to the limitations of 
the detection system using confocal microscopy, the results still throw doubts 
on the cell replacement, which suggests that other mechanisms may be 
involved in the survival of the impaired neurons in the SNc. Another possible 
explanation for the increased number of dopaminergic neurons after MSC 
transplantation is that MSC transplantation could rescue the damaged 
dopaminergic neurons from MPTP toxicity either by releasing neurotrophic 
factors which directly act on dopaminergic neurons or by suppressing immune 
response and protect dopaminergic neurons from further attacks. 
Emerging evidences suggest that IL-6 possesses neurotrophic 
properties (Juttler et al., 2002; Hakkoum et al., 2007). The up-regulated 
secretion of IL-6 from MSCs may protect dopaminergic neurons directly from 
the MPTP toxicity after transplantation. This finding is in accordance with the 
recent report that the sensitivity of dopaminergic neurons to a neurotoxicant 
was increased in the absence of IL-6 (Bolin et al., 2006).  
Recent publications indicate that MSCs have immune modulatory 
effects on peripheral inflammation (Di Nicola et al., 2002; Le Blanc et al., 2003; 
Jiang et al., 2005; El-Badri et al., 2004; Corcione et al., 2006; Uccelli et al., 
2006), which provide another explanation for the rescue effect of MSCs on the 
dopaminergic neurons in the MPTP-treated mice. 
5.2. Suppression of microglial activation after MSC transplantation 
The results of the present study demonstrated that systemic 
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administration of MSCs could suppress microglial activation in the SNc of 
MPTP-treated mice. In vitro studies further revealed the ability of MSCs to 
release several potent chemokines such as TGF-β1 and IL-6, which appeared to 
be capable of modulating the immune system and provide neuroprotection in 
the SNc. The current in vivo studies further revealed the ability of MSCs to 
release TGF-β1. TGF-β1 has been reported to have immune suppressive effect 
(Boche et al., 2006; Qian et al., 2008) and may suppress the microglial 
activation directly after MSC transplantation. Hereby, the transplanted MSCs 
could prevent TH positive dopaminergic neurons from further attacks by the 
neurotoxins released by activated microglia.  
5.3. Recovery of the impaired BBB  
To investigate whether MSCs transplantation would affect the BBB 
integrity, some tight junction molecules and the BBB function were studied. 
The results showed that MSCs transplantation could enhance the expressions of 
claudin 1, claudin 5 and occludin and restore the function of BBB impaired by 
MPTP-treatment. The underlying mechanisms may be firstly due to the 
cytokines, for instance TGF-β1, released by transplanted MSCs. Besides the 
immunosuppressive effects, TGF-β1 was also reported to maintain the 
functions of the BBB (Dohgu et al., 2004). The recovery of the BBB may also 
be resulted from the suppression of microglial activation which would lead to 
the down regulation of deleterious factors to the BBB. 
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5.4. Suppression of MBL infiltration after MSC transplantation 
After MSC transplantation, the author has also observed that the 
immune staining for either MBLA or MBLC in the SNc became negative. 
Since there was no MBL mRNA expression identified in the SNc after 
MPTP-treatment, the MBL was speculated to originate from peripheral 
circulation. Thus, the disappearance of MBL in the brain may be from the 
consequence of either the BBB recovery or downregulation of expression in 
hepatocytes. The disappearance of MBLA and MBLC in the SNc after MSCs 
transplantation was found in thr present study to parallel with the decreased 
expression of MBL in the liver. 
Taking together, the disappearance of MBL in the SNc of the brain 
may be a combined result of the repairing of the BBB to prevent the infiltration 
of MBLA and MBLC into brain parenchyma and inhibition in expression of 
MBLA and MBLC in the liver. This may lead to suppression in microglial 
activation in the SNc of the MPTP-treated mice and thereafter the survival of 
dopaminergic neurons. Thus, it is presumed that the protective effects of MSCs 
on dopaminergic neurons may be partially due to the immune suppressive 
effects of MSCs on the MPTP-induced neuroinflammation mediated via the 
MBL pathway. These findings further indicate that an effective control of the 
serum level of mannose binding lectins might be a novel therapeutic strategy to 
protect dopaminergic neurons in the PD model. 
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5.5. MSCs transplantation suppress the activation of NK cells in the SNc 
after MPTP-treatment 
NK cells are important components of the innate immune system. 
The present results have indicated the activation of NK cells via NKG2D 
receptor in the SNc of MPTP-treated mice. Interestingly, MSC transplantation 
suppressed this activation in the present study. Taking into account of other 
reports (Sotiropoulou et al., 2006; Spaggiari et al., 2008) that MSCs could 
suppressing the activation of NK cells in vitro, the author presumed that 
transplanted MSCs may protect dopaminergic neurons from the attack of NK 
cells by suppress the activity of NKG2D receptor in vivo.  
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Although the pathogenesis of Parkinson’s disease (PD) has been studied 
for many years, many issues on molecular mechanisms underlying the degeneration 
of dopaminergic neurons remain to be elucidated. Previous studies have 
histologically reported the degeneration of dopaminergic neurons and the 
pathological changes in the survived dopaminergic neurons in the SNc of PD 
patients. However, little is known about the molecular signals governing the 
degeneration or survival of the dopaminergic neurons in the SNc. The present study 
has demonstrated the involvement of microglial activation, BBB integrity 
compromise, MBL pathway and NK cell infiltration and activation in the 
degeneration of dopaminergic neurons in the MPTP-treated mouse PD model. 
The hypothetic processes of MPTP-induced dopaminergic neuron 
degeneration in the SNc in MPTP-treated mouse model have been proposed as 
follows (Fig. 45): 1) Administration of MPTP in mice could compromise the 
integrity of the BBB and decrease the expressions of tight junction molecules such 
as claudin 1, claudin5 and occludin. As a result, the permeability of blood vessels 
increased. 2) MPTP could enhance the synthesis of mannose binding lectin in the 
liver tissue. The over-expressed MBL could enter the brain parenchyma of SNc 
through the compromised BBB and bind to microglia, leading to activation of 
microglia. 3) Activated microglial cells could subsequently release inflammatory 
cytokines and neurotoxins, which may have deleterious effects on dopaminergic 
neurons directly or amplify the microglial activation to release more cytokines and 
exacerbate the dopaminergic neuron degeneration. 4) The increased permeability of 
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blood vessels could permit the penetration of more NK cells into the brain 
parenchyma and become activated under influence of local environment. Those NK 
cells may have cytolytic activity on the impaired dopaminergic neurons via NKG2D 
receptor. However, further investigations are necessary to study the underlying 
mechanisms of BBB compromise, MBL pathway reaction, microglial and NK cell 









Fig.45. Hypothetic processes of MPTP-induced dopaminergic neuron 
degeneration in the SNc in MPTP-treated mouse model 
         
Transplantation of MSCs in PD has been shown to have a protective effect 
on the dopaminergic neurons in the MPTP-treated model of PD. This protective 
effect may be due to multiple mechanisms (Fig. 46): 1) The systemically 
administered MSCs may be able to modulate the expression of MBL in the liver; 2) 
The MSCs may facilitate the repair of the damaged BBB; 3) As a result, the MSCs 
could suppress the activation of microglia and prevent the infiltration of NK cells; 4) 
MSCs may also directly modulate innate immunity or protect dopaminergic neurons 
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by releasing IL-6 and TGF-β1 after transplantation. Therefore, MSCs could exert 
their immune modulating functions in the treatment of PD.  







Fig.46. Hypothetic mechanisms of the protective effect of MSCs 
transplantation on dopaminergic neurons in the SNc of MPTP-treated 
mice. 
     
However, although MSCs could be induced to express neuronal markers in 
vitro, no neuronal marker expression was found in the present study in the MSCs in 
vivo. The transplanted MSCs may not be a good cell source for cell replacement 
strategy. In addition, the stem cells with genetic deficiency will inherit the same 
genetic deficiency as in the discovery of the present study that NFL-/- MSCs could 
differentiate to neuron-like cells with protein aggregation in vitro. Genetic 
background of stem cells must be carefully considered in cell replacement therapy.  
Overall, the present findings provide an important insight into the 
understanding of the pathogenesis of PD and the therapeutic role of systemic 
administration of MSCs. Although the results are only preliminary data, the present 
study has shed light on the involvement of the immune system in the pathogenesis of 
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PD, which revealed that MSCs as well as other immune modulators are of great 
importance in the treatment of this disease.
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bstract
Autologous bone marrow mesenchymal stem cell (MSC) transplantation has great potential in cell therapy used for the treatment of neurode-
enerative disorders. Since many genetic deficiencies have been reported in pathogenesis of the diseases, genetic backgrounds of donor stem cells
hould be concerned. In this study, effects of neurofilament light subunit (NFL) gene deficiency on proliferation and neuronal differentiation of
SCs were studied in vitro. Lower proliferation rate was observed in NFL−/− MSCs. When exposed to retinoic acid (RA), both NFL−/− and
ormal MSCs could express several markers of neuronal lineage, such as Nestin, MAP-2, NeuN, O4 and GFAP. However, the NFL expression at
RNA and protein levels was observed only in normal MSCs but absent in NFL−/− MSCs. Significant reductions in amount of neurofilament
eavy subunit (NFH) protein and number of neuron-like cells were detected in differentiated NFL−/− MSCs. Interestingly, NFH positive protein
ccumulations were observed in the neuron-like cells derived from NFL−/− MSCs. These accumulations were perinuclear and morphologically
imilar to protein aggregations in motoneurons of the spinal cord in NFL−/− mice. The results suggest that NFL gene deficiency could retard MSCs
roliferation and neuronal generation, even though the capability of neuronal lineage differentiation of MSCs may not be deterred. Moreover, the
FL−/− MSCs differentiated neuron-like cells carried on the genetic and pathologic deficiency, suggesting that the genetic quality of donor cells
ust not only be tested, but also modified before transplantation. This also points towards the possibility of creating a stem cell-derived cell model
or pathogenesis study.
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tem cell transplantation offers great hope in treatment of
eurodegenerative disorders. Although embryonic stem cells
nd stem cells derived from fetal brain have been considered
s candidates for transplantation therapy [5,7,20], limitations
n histocompatibility and ethical concerns would hinder their
linical application. Autologous stem cells, free from histocom-
atibility and ethical concerns, may therefore be advantageous
n cell therapy. MSCs are one of the most hopeful cell sources
n treatment of neurodegenerative diseases [3,4,8]. Experiments
ave shown that efficient induction of neurons, without glial
ifferentiation, could be achieved in human or rat MSCs by
ransfer of Notch1 intracellular domain gene plus adminis-
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ration of certain trophic factors [7]. In addition, glial cell
ine-derived neurotrophic factor could also effectively induce
ell differentiation from MSCs to dopamine-producing cells
nd result in functional recovery after such differentiated cells
ere grafted into the brain of Parkinson’s disease (PD) model
4].
For the cell replacement strategy, it is understandable that
he quality of donor cells must be considered because a large
umber of gene deficiencies or mutations are currently known
o be responsible for various neurodegenerative diseases. For
xample, -synuclein gene mutation has been confirmed to be
ssociated with familial PD [13] and SOD-1 mutation with
amilial amyotrophic lateral sclerosis (ALS) [14]. An intrigu-
ng possibility to consider is whether similar abnormalities in
ene expression occur in differentiated stem cells derived from





















































































alcohol, cleared in xylene and then mounted using permount.
For immunofluorescent method, the coverslips were mounted
on slides using Vectashield mounting medium. The staining
was viewed using conventional and confocal microscopes. NFH
Fig. 1. Lower proliferation rate of NFL−/− MSCs. Since NFL−/− and normalY.X. Chao et al. / Neuroscie
In this study, we have adopted the transgenic mice with tar-
eted disruption of NFL gene [21] to address our concern on
he issue of genetic background of stem cells in clinical applica-
ion. There are five types of intermediate filament proteins (IFs)
xpressed in mature neurons, including -internexin, periph-
rin and three neurofilaments, i.e., NFL, NFM and NFH. These
ubunits co-assemble as heteropolymers through their central
elical domain in normal mature neurons. The NFL deficiency
as been reported in some neurological disorders, including
lzheimer’s disease (AD), PD and ALS [17,18] and the sig-
ificant down-regulation in the expression of NFL mRNA has
een observed in degenerating neurons of ALS, PD and AD
2,10,11,19]. Furthermore, protein aggregation has been clearly
etected in vivo in the cytoplasm as well as processes of neu-
ons after targeted disruption of NFL because of mal-assembly
nd intracellular redistribution of IFs [21]. It is important to
ote that the abnormal accumulation of IFs in neurons is a
athological hallmark for many human neurodegenerative dis-
ases. Both clinical manifestations of NFL in neurodegenerative
iseases and several lines of converging evidence have shown
hat disruption of NFL may result in not only the formation
f protein aggregations in neurons but also retardation in neu-
onal proliferation in the spinal cord of NFL−/− mice during
evelopment [21]. This study has therefore examined the con-
equence of targeted disruption of NFL on MSCs proliferation
nd differentiation in vitro.
All procedures were in accordance with guidelines of Insti-
utional Animal Care and Use Committee. Ten NFL−/− mice
5 males and 5 females, a generous gift of Dr. M.J. Strong and
r. J.P. Julien) and 10 non-transgenic controls (5 males and 5
emales) of the C57BL/6J strain at 8–10 weeks of age were
mployed to obtain MSCs. A 22-gauge needle filled with Dul-
ecco’s Modified Eagle’s Medium (DMEM) was used to flush
ut whole bone marrow from the tibia and femur. The recovered
ells were filtered through a 70m mesh and plated in 75 mm
issue culture plates containing DMEM supplemented with 10%
etal bovine serum, 2 mM l-glutamate, 100 U/ml penicillin and
00g/ml streptomycin. Twenty-four hours later, non-adherent
ells were removed with total replacement of culture medium.
t confluency, the remaining adherent cells were further sub-
ultured at the 1:3 dilutions for 3 weeks. Finally, MSCs were
eady for subsequent experiments.
To determine whether targeted disruption of NFL gene could
mpose any inhibitory effect on MSCs growth, the prolifera-
ion was assessed using Cell Titer96TM AQueous One Solution
ell Proliferation Assay kit (Promega, USA). MSCs at a den-
ity of 5 × 103 cells/well with 200l medium were cultured in
6-well plates in triplicate at 37 ◦C and 5% CO2 environment.
he cell viability was measured at different time points for 7
onsecutive days according to the protocol provided by the com-
any. Briefly, 20l of MTS (5 mg/ml) were added into each
ell of 96-well plates for 4 h and then cell viability spectropho-
ometrically quantified using an ELISA plate reader at 490 nm
BioRad, USA). As no additional interruption in cell metabolism
nd no cell death were induced in the cultures, the disparity
n cell viability would therefore mainly represent the differ-
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enerated by serial dilution of normal MSCs, wherein the max-
mum was 5.1 × 104 cells/well and the minimum 2.55 × 103.
he number of MSCs was extrapolated from the standard
urve.
To study if differentiated neuron-like cells from NFL−/−
SCs would express NFL or NFH and form protein aggregates,
SCs at 80% confluence were trypsinized and then sub-cultured
n 6-well plates at a density of 1 × 105 cells/well with or with-
ut poly-l-lysine coated coverslips. Epidermal growth factor
20 ng/ml, Sigma, USA) was added to culture medium for 24 h
efore it was replaced with trans-retinoic acid (RA) (30M,
igma) containing media. The cultures were re-fed with fresh
edium containing 30M RA every 3 or 4 days. At 10 days
fter RA treatment, cells were studied by immunocytochemistry,
T-PCR and Western blot.
Neural differentiation of MSCs was demonstrated using
mmunohistological staining. RA-treated MSCs on coverslips
ere fixed in 4% paraformaldehyde for 10 min at room tem-
erature. After fixation, the coverslips were incubated with 5%
ormal serum for 1 h. Following blocking, rabbit anti-MAP2
1:500), rabbit anti-NeuN (1:1000), rabbit anti-glial fibrillary
cidic protein (GFAP) (1:1000), rabbit anti-NFH (1:5000),
abbit anti-O4 (1:1000) and mouse anti-Nestin (1:500, all anti-
odies from Chemicon, USA) were applied, respectively, at
◦C overnight. Specific labeling for various proteins was either
evealed by DAB colorization after the cells were processed
ith goat anti-rabbit or anti-rat secondary antibody for 1 h
nd Elite ABC complex for 30 min, or detected after incuba-
ion with secondary antibodies conjugated with FITC or Cy3.
or ABC method, the coverslips with cells were dehydrated inSCs were cultured in the same condition and no obvious cell death observed
n various time intervals, significant decreases in OD value of formazan product
n MTS assay in NFL−/− MSCs in comparison with that in normal MSCs at
ifferent time point have indicated less number of viable NFL−/− MSCs in the
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ositive neuron-like cells were blindly counted from three cov-
rslips of each group.
The expressions of NFL mRNA in RA-treated MSCs
ere analyzed with RT-PCR. Total RNA was extracted
sing RNeasy Mini Kit (Qiagen, USA). NFL sense primer
as 5′-atcagcaacgacctcaagtctat-3′ and antisense primer 5′-
actatacctgcatggcgctaat-3′ [21]. As the primer covers the
nockout domain of the peptide, it is possible to identify two
ifferent-sized mRNA, i.e., the normal NFL mRNA and dis-
upted NFL mRNA whereby a 720 bp fragment was replaced
y a 1000 bp neo cassette coding for neomycin. One micro-
ram of total RNA per sample was denaturated at 70 ◦C for
0 min. The RNA template was added to RT-PCR reaction
ixture containing 2l of reverse transcription 10× buffer,
mM MgCl2, 10 mM DTT, 1 mM dNTPs, 0.5g Oligo(dT)15,
unit/l RNAse inhibitor and 15 units/g AMV Reverse Tran-
criptase (Promega, USA). The final mixture was incubated
t 42 ◦C for 15 min and then 95 ◦C for 5 min. After reverse
ranscription reactions, cDNA amplification was performed in
final volume of 25l containing 1× PCR buffer, 0.2 mM




ig. 2. MSCs differentiation. After RA treatment, NFH−/− MSCs can be induced
ells, red), MAP-2 (B, for neurons, green), NeuN (C, for neurons, red), O4 (D, for
FAP and O4 staining, the nuclei are counterstained with DAPI (blue). A NeuN-pos
euN-negative cell. Both NFL−/− and normal MSCs could be induced to transdiffere
euron-like cells, perikaryal NFH positive accumulation is observed in immunohisto
ggregations can also be observed in the cytoplasm of motoneurons in the spinal cord
ll micrographs).etters 417 (2007) 240–245
nd 2 and 4l cDNA in the first and second rounds of PCR,
espectively. The reaction mixture was subjected to 40 PCR
ycles at 94 ◦C for 1 min and at 60 ◦C for 1 min. The last 3 min
f each PCR cycle were run at 72 ◦C. Final extensions were
erformed at 68 ◦C for 7 min before soaking of the amplified
CR products in −20 ◦C. The amplified PCR products were
lectrophoresed for 45 min at 95 V through 5% agarose gel con-
aining 0.5g/ml ethidium bromide. One hundred base pairs
NA ladder (Promega, USA) was used as a molecular weight
arker and gel was visualized under UV light.
Western blotting was employed to analyze expressions of
FL and NFH proteins. The cell homogenates (25g) were
eparated using 10% SDS-polyacrylamide gels and the pro-
eins electrotransferred to polyvinylidene difluoride (PVDF)
embranes. After incubation with 5% non-fat milk in 0.1%
ween-20 TBS (TTBS) for 1 h, the PVDF membrane was
hen incubated overnight with monoclonal antibody to NFL
1:500) or polyclonal antibody to NFH (1:5000) in 1% bovine
erum albumin in TTBS. The membrane was then incubated
ith horseradish peroxidase-conjugated goat anti-mouse IgG
1:5000) or goat anti-rabbit IgG (1:5000, Pierce, USA) for
to differentiate into cells expressing Nestin (A, marker for neural precursor
oligodendrocytes, green) or GFAP (E, for astrocytes, red). In MAP-2, NeuN,
itive cell with its nucleus stained in red (C) is observed to locate closely with a
ntiate into NFH positive neuron-like cells. However, in NFL−/− MSCs derived
logical staining (F, arrow), compared with the normal control (G). The protein
of NFL−/− mice (H, arrow), which serve as positive control (bar = 50m for










































Fig. 3. NFL gene expression. The primers were designed to cover neomycin
gene (1100 bp), the selective marker for NFL knockout by replacement of the
depleted NFL sequence (700 bp). The introduction of the neomycin gene into
the NFL depletion sequence has resulted in an increase in size of gene expressed




























bY.X. Chao et al. / Neuroscie
h at room temperature. Immunoreactivity was visualized
sing a chemiluminescent substrate (Supersignal West Pico,
ierce). Loading controls were carried out by incubating the
lots at 50 ◦C for 30 min with stripping buffer (100 mM 2-
ercaptoethanol, 2% SDS and 62.5 mM Tris–hydrochloride, pH
.8), followed by reprobing with a mouse monoclonal antibody
o-actin (1:5000 in TTBS, Sigma) and horseradish peroxidase-
onjugated anti-mouse IgG (1:5000 in TTBS, Pierce). Exposed
lms containing blots were scanned and the densities of the
ands measured using Quantity One Version 4 software (Bio-
ad). Densities of investigated bands were normalized against
hose of -actin and the mean ratios calculated. Cell prolif-
ration, differentiation and Western blot were analyzed using
NOVA. Significance was set at p < 0.05 or more stringent.
Although plating cell numbers were the same, NFL−/−
SCs grew in culture dishes at a lower density in compari-
on with normal MSCs when viewed at daily check-up. Trypan
lue staining showed that no obvious cell death occurred in the
ulture medium of both types of MSCs till at least 7 days of cul-
ure. However, the MTS assay has shown that the proliferation
f NFL−/− MSCs measured by viable cells was significantly
ower than that of normal MSCs (Fig. 1).
In vitro multiple-lineage differentiation of adult MSCs from
oth mice was confirmed based on our established protocols
6,9]. Especially, after the RA treatment, MSCs of both geno-
ypes have differentiated into Nestin(+) neural precursor cells,
AP-2(+) or NeuN(+) neuron-like cells, GFAP(+) astrocyte-
ike and O4(+) oligodendrocyte-like cells (Fig. 2A–E). RT-PCR
esults have confirmed that the RA treatment could induce
xpressions of NFH mRNA in both MSCs and NFL mRNA
n normal but not NFL−/− MSCs. Interestingly, an abnormal
and about 400 bp larger than normal NFL gene was detected in
FL−/− MSCs after the RA treatment (Fig. 3). In concert with
RNA expressions, the Western blot showed an absence in NFL
rotein expression in differentiated NFL−/− MSCs. Although
FH expression can be detected in both MSCs, a significant
eduction in amount of NFH protein was observed in differenti-
ted NFL−/− MSCs (p < 0.05) (Fig. 4). The number of NFH
ositive neuron-like cells increased from 9.92 ± 1.41 (with-
ut induction) to 33.39 ± 3.30 per 1000 cells (after induction)
n C57BL/6J MSCs but the increase was from 6.79 ± 0.59 to
2.73 ± 1.94 per 1000 cells in NFL−/− MSCs. Less neuron-like





ig. 4. Western blot analysis of NFL and NFH expressions. After RA treatment, NFL
e observed in both NFL−/− and normal MSCs, however, the amount of NFH (B) isuggesting that the quality of differentiated neuron-like cells might have been
ltered even though NFL−/− MSCs still possess the ability to differentiate into
euron-like cells.
n comparison to C57BL/6J MSCs (p < 0.01). Significantly,
ense protein accumulation indicated by NFH immunostaining
as found in the cytoplasm of differentiated NFL−/− MSCs
Fig. 2F) and the number of neuron-like cells with protein aggre-
ation increased to 8.04 ± 2.32 per 1000 cells at 10 days after
nduction, in comparison to 1.61 ± 1.62 per 1000 cells with-
ut induction (p < 0.01). No such dense NFH accumulation was
ound in the cytoplasm of normal MSCs with or without the RA
reatment (Fig. 2G). Morphologically, the protein accumulation
ocated at perinuclear position greatly resembled protein aggre-
ation in the cytoplasm of motoneurons in the spinal cord of
FL−/− mice (Fig. 2H).
It would be ideal to replace diseased or injured neurons
ith newly generated neurons from self-originated stem cells
n cell therapy. Although MSCs from the bone marrow have
een confirmed to possess stem cell properties of self-renewal
nd multi-transdifferentiation, doubts are still cast on the ability
f MSCs to differentiate into neurons. In this study, we have
mployed the neurodegenerative mouse lack of NFL to isolate
dult MSCs and demonstrated their ability in neural transdiffer-
ntiation from another point of view.
Neurofilaments are important and specific molecular compo-
ents of neurons which are normally involved in the maintenance
f neuronal caliber [1,16]. In concert with other reports [4,6,9],
ur results showed that MSCs from both mice could be induced
y the RA treatment to express GFAP, O4, Nestin, MAP-2 or
euN, suggesting that MSCs possess neuronal lineage differ-
ntiation potential. Our results further demonstrated that MSCs
rom normal mice could differentiate into cells expressing both
expression (A) is totally absent in NFL−/− MSCs. NFH expression (A) can
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FH and NFL, pointing out another evidence of neuronal prop-
rties of differentiated MSCs. Interestingly, no NFL expression
t both mRNA and protein levels was detected in differentiated
FL−/− cells after the RA treatment. However, the dense per-
nuclear protein accumulation indicated by NFH staining was
bserved in some differentiated NFL−/− cells and morpholog-
cally the NFH-positive protein aggregation was similar to that in
he cytoplasm of the motoneuron in the spinal cord of NFL−/−
ice. The neurofilament aggregations in the perikarya of neu-
ons are thought to be caused by the failure in normal assembly
f NFL, NFM and NFH triplets after the targeted disruption of
FL in mice [21]. Protein accumulation is one of hallmarks in
eurodegenerative diseases, such as ALS [21], PD [18] and AD
17]. Although NFL gene may not be a real causative factor for
D [15], down-regulation of NFL mRNA expression has been
eported in some cases of these diseases [2,10,11,19]. The abil-
ty of MSCs to differentiate into protein aggregate-containing
euron-like cells in this study has definitely not only added
urther token to the MSC potential in generation of neurons,
ut also provided a possible approach as a cell model to study
athogenesis of neurodegenerative diseases.
There were about 20% less neurons in the spinal cord
f NFL−/− mice [21], suggesting a deficiency in neuronal
ifferentiation in neuronal progenitors. In agreement with dif-
erentiation deficiency of neuronal progenitors in vivo, our cell
roliferation assessment has shown a significant decrease in pro-
iferation of MSCs in vitro in comparison with that in normal
SCs. Significant reductions in amount of NFH protein and in
he number of neuron-like cells in differentiated NFL−/− MSCs
ompared with that in differentiated normal MSCs may also
ndicate a deficiency in neuronal differentiation. Although we
o not understand the exact mechanism involved in this reduced
roliferation and neuronal differentiation in both neuronal pro-
enitors and MSCs, NFL might be somehow important for stem
ell renewal and differentiation both in vivo and in vitro.
In conclusion, the generation of protein-accumulating neu-
ons in vitro has not only confirmed the neuron generating ability
f MSCs but also points out a serious concern for application of
tem cells in cell therapy, where the differentiation could inherit
he feature of the original gene deficiency. The newly generated
enetically deficient cells might not be able to fulfill the purpose
f replacement of original diseased cells because the adult stem
ells may possess the same genetic deficiency and the embryonic
tem cells may have other genetic deficiencies. It is important in
ell replacement strategy to monitor the stem cell genetic back-
round and to modify the genetic deficiency if any is present.
owever, diseased neuron-like cells generated from stem cells
ay serve as a cell model for studying mechanism involved in
athogenesis and treatment.
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